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Muktasari 
Ugonjwa wa UKIMWI umeathiri takribani watu milioni 70 ulimwenguni kote na kuua karibu 
nusu ya watu wote waliokwishambukizwa. Madawa ya kufubaza virusi vya ukimwi 
vimefanikiwa kuokoa vifo na kufanya waathirika wa UKIMWI kuishi maisha ya kawaida 
mithili watu wasioambukizwa virusi hivyo. Licha ya mafanikio makubwa kutokana na haya 
madawa, bado kuna changamoto kadha wa kadha zinazofanya madawa haya yasipatikane au 
yasitumika kama ilivyokusudiwa. Changamoto hizi ni uhaba/ukosekanaji/uadimikaji wa 
madawa kwenye kliniki za matibabu, ufuasi mbaya wa madawa na usugu wa virusi 
vinavyofanya virusi kuendelea kuzaliana japo muathirika wa ukimwi anatumia dawa. 
Jukumu la kwanza ilikua ni kutafiti uhaba wa madawa katika wilaya mbili zilizoko nje ya miji 
mikubwa katika nchi ya Tanzania wakati ambako huduma za UKIMWI zilipokuwa 
zimesogezwa karibu zaidi kwa wananchi waishio mashambani. Utafiti umeonyesha kuwa 
katika kipindi cha mwaka mmoja kabla ya utafiti huu, vituo viliishiwa vitenganishi vya 
upimaji wa virusi vya ukimwi, madawa ya kotrimaksozoli na madawa ya kufubaza virusi vya 
ukimwi. Katika harakati za kukabiliana na janga hili, baadhi ya mbinu ambazo watumishi wa 
kliniki na wagonjwa walitumia zingeweza kuongeza matata zaidi kwa wagonjwa wa ukimwi. 
Tumependekeza ukusanyaji sahihi wa madawa na kutumia taarifa hizo kuagiza madawa kiasi 
cha kutosha kwa kipindi husika.  
Jukumu la pili lilikua ni kutafiti ufuasi wa madawa miongoni mwa waathirika wa ukimwi 
waliokwisha anza kutumia madawa ya kufubaza virusi vya UKIMWI. Tuligundua kuwa 
watoto wanaolelewa na walezi wasio wazazi wao walikua katika hatari ya kuwa na ufuasi 
mbaya kuliko watoto waliokua wanalelewa na walezi ambao pia ni wazazi wao. Wagonjwa 
walio masikini pamoja na wagojwa waishio karibu na kliniki ya Ifakara walikua na 
uwezekano mkubwa wa kuwa na ufuasi mbaya wa madawa. Utafiti umezidi kuonyesha kuwa 
wakati wa msimu wa kilimo watu wengi walionyesha ufuasi mzuri wa madawa kuliko wakati 
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wa kiangazi. Unyanyapaa dhidi wa waathirika wa ukimwi umeonyesha kusababisha 
wagonjwa kutokua na ufuasi mzuri wa dawa za ukimwi. Tumependeza kufanyika kwa 
kampeni za kuzuia unyanyapaa na umezaji wa dawa mbele ya shahidi kwa wagonjwa watoto 
wenye uwezekano mkubwa wa kua na ufuasi mbaya wa madawa.  
Katika jukumu yetu ya mwisho tuliokusudia kutafiti vielelezo vinavyochechea usugu wa 
madawa ya ukimwi, tumegundua kuwa watu wenye umri chini ya miaka 18 walikuwa na 
uwezekano mkubwa zaidi wa kuwa na virusi vyenye usugu wa dawa ukilinganisha na watu 
wenye umri zaidi ya miaka 18. Hii inaweza kua imesababishwa na utoaji wa dawa moja tu 
(badala ya tatu kama ilivyo sasa) ya nevirapine kwa akina wanawake wajawazito na ufuasi 
mbaya wa madawa kwa wagonjwa wenyewe. Ili kukabiliana na janga hili tumependekeza 
kuwa mbinu za kuongeza ufuasi utumike na teknolojia isiyo kuwa ya gharama kutumika 
katika kufuatilia kuzaliana kwa virusi wakati mhusika anapokua kwenye dawa za ukimwi. 
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Summary 
 
HIV is one of the worst pandemics in recent times, having affected more than 70 million and 
with a mortality rate close to 50%. Antiretroviral drugs fight viral replication and has 
improved life of HIV infected patients since it was introduced. Although ART has the 
potential of transforming the fatal disease into a chronic condition, there are critical issues 
surrounding access, adherence and resistance to the dug. We have systematically studied these 
questions and proposed a way forward to make ART more effective. 
The first study explores the stock-out experience in two districts in rural Tanzania at the time 
when ART decentralization had just taken place. Out of stock was not a strange phenomenon 
with all sites have experienced stock-out of HIV test kits. The patients in the CTCs 
experienced HIV drugs and cotrimoxazole stock-out in the year preceding the study. Some of 
the strategies used appear to aggravate problems.  
The adherence studies were showed parental caretaking a strong predictor of adherence in 
children and poverty and proximity playing acted as barrier to optimal adherence. ART 
adherence reporting overtime shows, patients tend to have better adherence during 
agricultural season. De-stigmatization campaigns and Direct Observed Therapy (DOT) 
interventions to children at risk of non-adherence are may improve adherence. 
In our last study on predictors of ART resistance, children were more likely than adults to 
have resistances mutations. This might be linked with either the previous use of a single dose 
nevirapine and/or with non-adherence as observed in the adherence study. Improving 
adherence and low cost viral load monitoring may be appropriate solutions. 
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1 CHAPTER ONE: Background 
1.1 Origin of HIV/AIDS  
AIDS was first recognized in the United States of America (USA) in 1981 with reports of 
unexplained opportunistic infections including Pneumocystis jirovecci pneumonia and kaposi 
sarcoma among homosexual men in New York and San Francisco (Durack, 1981; Gottlieb et 
al., 1981; Masur et al., 1981). In 1983, a retrovirus called lymphadenopathy associated virus 
(LAV) or Human T-Cell Lymphotropic Virus III (HTLV III which was later renamed Human 
Immunodeficiency Virus) that kills T cells was isolated from the lymphatic system of a gay 
AIDS patient. (Barre-Sinoussi et al., 1983). Further research showed that AIDS is caused by 
the human immunodeficiency virus (HIV), which originated from non-human primates in 
Sub-Saharan Africa (SSA) and was transferred to humans during the late 19th or early 20th 
century. The HIV-1 strain is either closely related to the Simian immunodeficiency virus 
(SIV) that infects the chimpanzee subspecies Pan troglodytes troglodytes (SIVcpz), or to the 
SIV that infects Western lowland gorillas called SIVgor (Van Heuverswyn et al., 2006). HIV-
2 is closely related to SIV from sooty mangabeys (SIVSM). The mutated simian virus became 
the first HIV (Pickrell, 2006).  
Two types of HIV are known: the most common is HIV-1, which is responsible for the 
worldwide AIDS epidemic, and the immunologically distinct HIV-2 (Clavel et al., 1986). 
Both viruses have similar transmission routes, cellular targets, and AIDS-defining HIV-
related symptoms. However, as compared with HIV-1 infection, HIV-2 infection is 
characterized by lower transmission rates, a longer asymptomatic stage, a slower decline in 
CD4+ T-cell counts, and a lower mortality rate (De Cock et al., 1993; Kanki et al., 1994; 
Marlink et al., 1994; O'Donovan et al., 2000).  
The HIV-1 type itself includes four groups M (main), O (outlier), N (non-M, non-O) and P, 
which have different geographic distributions but produce similar clinical symptoms 
(Ariyoshi et al., 1999; Burke, 1997; Plantier et al., 2009; Robertson et al., 2000; Vallari et al., 
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2011). The M group is further split into 9 subtypes (A through J), as well as at least 58 
circulating recombinant forms (CRF) and multiple unique recombinant forms (URFs). HIV-2 
is more concentrated in West Africa and can be classified into 8 groups (A–H), with only one 
CRF, named CRF01_AB, (Ibe et al., 2010) and a novel HIV-2 variant, recently identified in 
Ivory Coast (Ayouba et al., 2013).  
Most of the available epidemiological data indicate that the extensive spread of HIV started in 
SSA in the late 1970s. By the early 1980s, HIV was found in a geographic band stretching 
from West Africa across to the Indian Ocean, the countries north of the Sahara and those in 
the southern cone of the continent remained safe. Currently, countries in North Africa and in 
the horn of Africa have significantly lower prevalence rates, as their populations typically 
engage in fewer high-risk cultural patterns that have been implicated in the virus's spread in 
SSA (UNAIDS, 2010; Velayati et al., 2007). By 1987, the epidemic began gradually to move 
to southern parts of Africa where some of the most explosive epidemics have been seen in 
Southern Africa. South Africa has the largest number of people living with HIV/AIDS in the 
world, 5 million. Botswana and Swaziland have the highest prevalence levels, 38% and 33% 
respectively. HIV disproportionately affects sex workers, men who have sex with men and 
people who inject drugs across the world (UNAIDS, 2012b). In Tanzania, the first cases of 
HIV-1 infection were observed and reported in the Kagera region in 1983 (National Aids 
Control programme, 2005), and by 2011, it was estimated that 1.6 million Tanzanians were 
living with HIV/AIDS (UNAIDS, 2012g). The disease has orphaned 1.3 million children. An 
estimated 150,000 Tanzanians were newly infected with HIV in 2011, which is over 400 new 
infections every day (UNAIDS, UNAIDS (2012) ). In the same year, 83,528 Tanzanians died 
from AIDS. 
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1.2. Treatment of HIV/AIDS 
1.2.1.1 Antiretroviral Therapy (ART) 
After the discovery of HIV/AIDS in 1981, no drug was available to treat the infection until 
1987 when Zidovudine was approved by the US Food and Drug Authority (FDA) (Wright, 
1986). The drug was used as monotherapy for many years before combination antiretroviral 
therapy (ART) was introduced 10 years later. To date, there is no cure for HIV/AIDS disease 
but ART is used to inhibit viral replication thus delaying progression to AIDS. There are 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion inhibitors (FIs), CC chemokine 
receptor 5 (CCR5) and Integrase inhibitors (INIs). NRTIs, NNRTIs and PIs are the drugs 
widely available in developing countries. The NRTI slow down the production of reverse 
transcriptase enzyme and make HIV unable to infect cells and reproduce. The NNRTI 
(approved in 1997) block the reverse transcription of viral RNA genome in cDNA which is 
catalysed by reverse transcriptase. The PIs (introduced in 1995) block the protease mediated 
maturation of released virions. The FIs and CCR5 antagonists block HIV entry into cells. The 
INIs block the integration of viral genome into the DNA of the host cell. 
1.2.1.2 Monitoring of treatment 
Low-and middle-income countries (LMIC) have adopted the WHO public health approach as 
the standard for ART delivery and monitoring of HIV patients (Gilks et al., 2006; UNAIDS, 
2012d). The public health approach seeks to ensure the widest possible access to high-quality 
services at the population level, balancing the best evidence-based standard of care with the 
feasibility of large-scale implementation in resource-limited settings (Hirnschall et al., 2013). 
This involves scaling up Voluntary Counseling and Testing (VCT), standardizing and 
simplifying ART and monitoring patients CD4 when possible. CD4 count and viral load are 
both strong predictors of disease progression and survival regardless of whether a patient is on 
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treatment or not (Egger et al., 2002; Hughes et al., 1998; Marschner et al., 1998; Mellors et 
al., 1997; Mellors et al., 1996; Murray et al., 1999; O'Brien et al., 1996; Thiebaut et al., 2000). 
Since 1996, viral load testing has been a key component of standard care in HIV treatment in 
developed countries.  
1.2.1.3 Benefits of ART 
1.2.1.3.1 Suppression of virus 
A detectable viral load implies on-going viral replication, which fosters the development of 
drug-resistant mutations and constitutes a major potential problem for the future of ART 
(Katzenstein et al., 1996; Lundgren et al., 2002). Drug-resistant strains of HIV selected 
through lower ART levels can be transmitted to uninfected or drug-naive patients, leaving 
them with fewer treatment options (Wainberg et al., 1998). However, despite advances in 
antiretroviral therapy, some treatments still fail. A major cause of treatment failure is the 
development of drug resistance in HIV-1 B and non-B subtypes (Clavel et al., 2004; Deeks, 
2000; Karmochkine et al., 2000; Miller et al., 1998; Parikh et al., 2012; Praparattanapan et al., 
2012; Wainberg et al., 1991). The extreme variability and the high evolution rate of HIV-1 
favour the development of antiretroviral resistance. Indeed, HIV-1 infection is characterized 
by a high degree of genetic variability within infected persons.  Although a dose–response 
relationship between adherence and virologic suppression exists, some patients with high 
levels of adherence to NNRTI–based ART experience virologic failure, whereas others with 
suboptimal adherence do not (Bangsberg, 2006; Nachega et al., 2007). This has been 
interpreted as some drugs (NNRTI) being more forgiving of suboptimal adherence drugs than 
others (non-boosted PI) as suggested in observational studies and a randomized controlled 
trial (Bangsberg, 2006; Maggiolo et al., 2005). This is because of the longer half-life and 
greater potency of NNRTI regimen (Moore et al., 2005; Staszewski et al., 1999). 
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1.2.1.3.2 Reduction of HIV Transmission  
Antiretroviral therapy reduces the risk of HIV transmission by up to 96% (Cohen MS et al., 
2011). There are three ways in which these drugs can be deployed to prevent infections: as 
post-exposure prophylaxis, as pre-exposure prophylaxis, and to reduce infectiousness of HIV-
infected people to their sexual partners (treatment as prevention. HIV transmission is reduced 
at lower viral loads (Gray et al., 2001; Quinn et al., 2000), therefore ART could theoretically 
reduce HIV incidence and potentially be used to control the epidemic. Once-daily oral 
administration of the fixed-dose combination of emtricitabine (FTC) and tenofovir disoproxil 
fumarate (TDF) [FTC/TDF; Truvada], which is recommended as part of first-line 
antiretroviral regimens to treat HIV-1 infection (Adolescents, 2012), is the first (and currently 
the only) antiretroviral regimen approved (in the USA) for pre-exposure prophylaxis of HIV-1 
infection .  
1.3 ART challenges 
1.3.1 Health system issues 
1.3.1.1 Access 
Introducing ART particularly to SSA was debated controversially because of concerns about  
poor infrastructure, logistic, human capacity, cost-effectiveness, adherence and subsequent 
development of drug resistance (WHO, 2003). However, a feasibility study by the World 
Health Organization (WHO) about access to ART catalyzed global efforts and ART has been 
significantly scaled up (WHO, 2010d). In 2006, the member states of the United Nations 
agreed to aim for universal access (rollout of ART) to treatment in 2010 (WHO et al., 2007). 
Access to ART in SSA has improved considerably over the past years and has contributed to 
decreased HIV/AIDS morbidity and mortality in the region (Badahdah et al., 2011; Mills et 
al., 2011; UNAIDS, 2012e). The global scale-up of ART over the past decade represents one 
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of the greatest public health achievements of recent times. The number of patients on ART 
has dramatically increased by more than 26-fold between 2003 and 2011 in resource-limited 
settings (World Health Organization, 2012). A combination of efforts has made it possible to 
get nearly ten million HIV positive patients onto ART (AIDS et al., 2008; Mutevedzi et al., 
2010; Stringer et al., 2006; Toure et al., 2008) and 54% of people who are eligible for 
treatment in the developing world receiving ART (UNAIDS, 2012e). Access to pediatric ART 
in resource limited settings has risen more than 7-fold from 75,000 children receiving ART in 
low and middle income countries in 2005 to 562,000 by the end of 2011(WHO, 2013c). This 
success has accelerated efforts to reach the UNAIDS goal of treating 15 million people by 
2015 (PEPFAR, 2012; UNAIDS, 2012f). Two countries in SSA, Botswana and Rwanda, have 
achieved the universal access target (treatment coverage of 80% or more of patients in need) 
at the end of 2009 (WHO, 2010d), while countries such as Ethiopia, Zambia, Namibia, and 
Senegal are moving closer to the target having covered 50–80% of patients in need of 
treatment (WHO, 2010d). ART was introduced to Tanzania in 1995 with mono and dual 
regimens available to only a small number of patients due to the high cost of the drugs 
(Kasang et al., 2011; G. R. Somi et al., 2008). Access to ART has increased since the 
Tanzanian government launched its public-sector ART program free of charge in October 
2004 (Kasang, Kalluvya et al., 2011; G. R. Somi, Kibuka et al., 2008). ART coverage in 
Tanzania has been steadily rising since 2004, with a coverage rate of 52% by 2012 (UNAIDS, 
2012a).  
HIV stigma is still a big problem hindering HIV testing and ART use among HIV infected 
patients. HIV stigma described as prejudice and discrimination that are directed at people with 
HIV/AIDS (Herek et al., 1998) is a universal phenomenon (UNAIDS, 2002). Disclosure of 
HIV status open up the potential for stigma and the shame of being HIV positive (Landau et 
al., 2004) and the experience of disclosing has been documented as traumatic. Stigmatizing 
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attitudes about HIV/AIDS leading to fears of discrimination can influence decisions to seek 
HIV testing and HIV treatment services(Hull et al., 1988). AIDS stigmatizing beliefs 
represent potential barriers to seeking HIV testing (Herek et al., 2003). 
1.3.1.2 Procurement supply chain management 
With an unabated growth of ART cohorts managed at an ever-increasing number of facilities, 
procurement and supply chain management (PSM) systems for HIV/AIDS medicines in 
resource-constrained countries are facing critical challenges, and problems in the PSM 
systems are becoming a growing concern (Schouten et al., 2011). A WHO survey in 2009 
revealed that 38% out of 94 reporting countries had documented at least one stock out of ART 
in health facilities (WHO, 2010d). Interrupted supply of ART puts individual patients at risk 
of disease progression and death [3], jeopardizes public health due to development of ARV 
drug resistance, hampers progress towards universal access, and diminishes the credibility of 
ART programme in the eyes of patients, the community and healthcare providers. An increase 
and spread of ART resistance will necessitate a change of first-line regimens, and these are 
without exception more expensive and increase the costs of national ART programmes.                                                        
1.3.1.3 Cost 
In the presence of resource constraints, the sustainability of ART access clearly depends on 
affordable prices for the drug active pharmaceutical ingredients (API). Throughout the 1990s, 
the annual cost of drugs for AIDS treatment often exceeded US$10,000 per patient (A. S. 
Nunn et al., 2009; Outterson, 2006).  Demand for APIs to produce generics locally created 
economies of scale for generic ART. This in turn contributed to declining unit costs of generic 
ART, which, with new donor funding, contributed to developing countries’ demand for 
generic ART, as well as APIs. This induced new generic firms to enter the ART market, 
increasing competition and further contributing to declining drug prices. India has emerged as 
a world leader in generic pharmaceuticals production, supplying 20% of the global market for 
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generic medicines. The emergence of generic sources supplying quality ART at prices much 
lower than originator prices has accelerated the global scale up of HIV/AIDS treatment. Price 
reductions noted for commonly used historical first-line regimens were a result of robust 
generic competition among Indian manufacturers in an environment largely void of 
intellectual property barriers (Ford et al., 2007). Since 2001, the pharmaceutical companies 
Roche, Gilead, Merck, Abbott, and Bristol-Myers Squibb have dropped their ART prices and 
introduced tiered pricing in many developing countries. Formerly a high-margin, low-volume 
model, the ART market has become a low-margin, high-volume model.  
New intellectual property obligations for generic drugs can increase ART prices, impede the 
development of acceptable dosage forms, and delay access to newer and better HIV drugs. 
Such measures can undermine the international goal to achieve universal access to HIV/AIDS 
interventions and the 2001 WTO Doha Declaration on TRIPS and Public Health (World 
Health Organization, 2007). Arusha-based Tanzania Pharmaceutical Industry (TPI) has been 
producing ARVs but was suspended by the Tanzanian government in 2012 over 
manufacturing of fake ART (Rose Athumani, 2012). Under the World Trade Organization's 
trade-related aspects of intellectual property rights, poor countries like Tanzania are permitted 
to produce essential drugs without pharmaceutical product patents until 2016 (World Trade 
Organization, 2003). 
1.3.1.3 Human resource, governance and training 
The main limitation for ART scale-up in Tanzania is the low number and low productivity of 
clinical staff (Hanson et al., 2009). The shortage of staff limits both recruitment of new 
patients for ART and further reduction of the number of AIDS deaths. According to the 2009 
Tanzanian care and treatment plan, CTCs should be located at hospitals and run by treatment 
teams of 18 staff members including 7 counsellors (UNITED REPUBLIC OF TANZANIA, 
2003). Since the IMF-induced hiring freeze of government health staff in 1993, the total 
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number of health workers dropped from 67,000 in 1995 to 54,000 in 2002 and has been 
estimated to fall even further to 49,000 by 2015 (Kurowski et al., 2007). The IMF freeze was 
lifted after 11 years and the outputs from medical training institutions have increased 
(MOHSW, 2006), but many of these were recruited from within the workforce and as 
recruitment of new staff is a slow process (OECD/DAC, 2007) it will take several years 
before any real increase in staff numbers can be achieved. Responsible governance is crucial 
to national development and a catalyst for achieving the targeted treatment outcomes (Siddiqi 
et al., 2009). Governance seems a neglected issue in the field of human resources for health 
(HRH) but achieving attention in health systems (Dieleman et al., 2011) and thus why HRH 
policy formulation is poor. In Tanzania, it was found that decentralization of health services 
increased flexibility in planning and ownership of local services but also actually worsened 
distribution imbalances between areas in Tanzania rather than improving them (Munga et al., 
2009).There is a shortage of HRH in Tanzania, low skill levels; most training is in-service, high 
staff rotation and inefficient distribution of staff the Tanzanian health sector (Wales et al., 2014). 
1.3.2 Individual level issues 
1.3.2.1 Adherence 
Apart from AIDS, no other infectious disease has required lifelong therapy, and the 
challenges of equitable treatment of this chronic infectious disease are daunting; not the least 
among them is lifelong adherence to medications. Adherence is the single most modifiable 
factor that predicts treatment outcome among patients on ART. Adherence is defined as 
taking medications correctly according to prescription. According to recent studies, ART 
regimens require 70–90% adherence in order to be effective (Nachega et al., 2010). Rates of 
adherence in Africa have been reported as high as more that 90% (Amberbir et al., 2008; 
Coetzee et al., 2004; Oyugi et al., 2004) and a systematic review published in 2006 suggested 
that adherence, measured using quantitative indicators, was considerably better in Africa than 
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in the United States (Mills et al., 2006).  In early treatment period characterized by a heavy 
viral burden, a higher adherence is required than the late treatment period when viral 
suppression is achieved (Carrieri et al., 2003). There are different methods for assessing 
adherence and the level of adherence is specific not only to places and patient groups but also 
to the method of adherence measurement used (R. J. Landovitz, 2011). Currently, there are no 
gold standard methods for measuring adherence (Nachega, Mills et al., 2010). Adherence 
measures include direct methods such as biologic markers and body fluid assays, or indirect 
methods such as self-report, caregiver report, interview, pill counts, pharmacy records, 
computerized medication caps, and viral load monitoring. While a combination of these 
methods may be employed, patient self-report is the most widely used (Vreeman et al., 2008a)  
given its ease of implementation and use of already existing resources. Studies have also 
indicated that self-reports correlate well with both viral load and clinical outcomes (Liu et al., 
2001; Nieuwkerk et al., 2005). In developing countries, pharmacy refill reports and self-
reports are commonly implemented for adults (Chesney, 2006; Nachega, Mills et al., 2010), 
while caregiver reports are employed for children. A number of studies have reported barriers 
to good adherence to antiretroviral therapy in the initial period after enrolment on to care, 
which have included: costs of visiting clinics to access care (Castro, 2005), which can be as 
high as 10-20% of monthly salary/wages per visit (Hardon et al., 2007; Jaffar et al., 2009), 
occurrence of unpleasant side effects, such as lipodystrophy (Chesney, 2000; M. O. Johnson 
et al., 2007) and HIV-associated stigma (Dlamini et al., 2009; Mahajan et al., 2008). Even 
people with typically excellent adherence will experience treatment interruptions owing to 
inevitable disruptions in daily routine, relapse of substance use or mental illness, or simple 
pill fatigue. Sub-optimal adherence can lead to periods of effective monotherapy (the presence 
of just one drug above the minimally effective concentration) when drugs have very different 
half-lives. Effective monotherapy is most likely to occur in patients on NNRTI-based 
treatments, because NNRTIs typically have longer half-lives than NRTIs (Bangsberg et al., 
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2006). As such, adherence support may be necessary for many, if not most, people at some 
time in the course of life-long treatment in order to achieve the full individual and public 
health impact of antiretroviral therapy.   
1.3.2.2 Loss to follow-up  
The evidence continues to highlight the urgent need to improve retention rates for people 
enrolled in HIV care and treatment. Loss-to-follow-up (LTFU) (non-attendance at scheduled 
clinic visits) in HIV programmes in SSA is important among those eligible for ART, given 
the risk of mortality and morbidity, onward transmission and ART resistance with 
inconsistent medication use (Cornell et al., 2010). High levels of attrition from HIV 
programmes in SSA have been reported in the period between the assessment of individuals 
as ART eligible and treatment initiation (Rosen et al., 2011). For those who have started ART, 
attrition rates of 23% at one year, 25% at two years and 30% at three years in SSA have been 
estimated (Fox et al., 2010). A number of clinical, demographic and structural factors have 
been shown to relate to higher rates of LTFU in individuals on ART (or those eligible to start 
ART) in SSA. Clinical correlates of higher LTFU include both lower (Togun et al., 2011), and 
higher CD4 count (Mutevedzi et al., 2013; Van Cutsem et al., 2011), poorer adherence to 
ART (Karcher et al., 2007) and TB co-infection (Bassett et al., 2012; Tayler-Smith et al., 
2011). Demographic correlates of LTFU include male gender(Charurat et al., 2010; Karcher, 
Omondi et al., 2007), younger age (Cornell, Grimsrud et al., 2010; Van Cutsem, Ford et al., 
2011; Wang et al., 2011), pregnancy for women (Wang, Losina et al., 2011), lower levels of 
education(Charurat, Oyegunle et al., 2010), financial constraints (Cornell et al., 2009), and 
migration (Mutevedzi, Lessells et al., 2013), (Bygrave et al., 2010). Structural correlates 
include less distance to a tarred road (Mutevedzi, Lessells et al., 2013), later calendar year of 
ART initiation (Van Cutsem, Ford et al., 2011) and increased time on ART (Van Cutsem, 
Ford et al., 2011). Nearly half of all people who initiated antiretroviral therapy at the same 
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treatment centre in Malawi were no longer in care five years later, and this proportion was 
nearly 40% in Kenya(UNAIDS, 2012c). A study conducted in four countries SSA found that 
community supported models of care for people on HIV treatment improved retention; 
reduced indirect medical cost (travel and lost income) and the number of clinical visits 
(Bemelmans et al., 2014). A meta-analysis covering 13 African countries suggests that 40% 
of all ART clients might have died or discontinued treatment within 2 years after treatment 
initiation (Rosen et al., 2007). The attrition rate of patients from care and treatment 
programmes in Tanzania is high, highlighting the need for concerted efforts to improve 
tracing mechanisms to document the true outcomes for these patients and to encourage them 
to return to care in the case of default (NACP, 2013b). 
1.3.3 ART outcome 
1.3.3.1 Virological failure 
Virological failure is the inability to achieve or maintain viral suppression to an HIV RNA 
level below detectable limits. It is generally believed that drug resistance associated mutations 
do not occur in patients with HIV RNA levels persistently suppressed to below the lower 
limits of detection (LLOD) of recent assays (Kieffer et al., 2004). After ART initiation, most 
patients experience improved immune function and maintain viral suppression; however, 
there remains a subset of patients who have suboptimal immunologic responses. In ART-
naive patients on initial regimens, during the first year of ART initiation, CD4 counts usually 
increase by approximately 150 cells/mm
3
 (Bartlett et al., 2001). A CD4 count plateau may 
occur after 4 to 6 years of treatment with suppressed viremia (F. Garcia et al., 2004; 
Kaufmann et al., 2003; Lau et al., 2007; Mocroft et al., 2006; Moore et al., 2007; Tarwater et 
al., 2001). Studies have attributed treatment failure to previous ART exposure, non-adherence 
or treatment interruptions and drug resistance. A study done in Tanzania and South Africa 
showed an increased risk of virologic failure in previously ART exposed HIV positive 
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patients (El-Khatib et al., 2011; Ramadhani et al., 2007). The trend is similar when children 
are exposed to single-dose nevirapine in prevention of mother-to-child transmission (PMTCT) 
(Stringer et al., 2010). A cross-sectional relationship between adherence and virologic 
suppression has been demonstrated in Brazil (R. Garcia et al., 2006) and a sub-optimal ART 
was associated with lower virologic success in Cambodia (Segeral et al., 2011). Treatment 
interruptions are associated with the development of ARV resistance (Bansi et al., 2008; 
Martinez-Picado et al., 2002; Oyugi et al., 2007; Parienti et al., 2004). Treatment failure needs 
to be detected early enough to minimize the effect it has on increased morbidity and mortality 
among patients on ART. Possible solutions to treatment failure include appropriate switch to 
second-line regimen or further adherence support (Abrams et al., 2013). 
1.3.3.2 Drug resistance 
Antiretroviral drug resistance is a result of substitution of some amino acids in the HIV 
Reverse Transcriptase (RT) and protease enzymes. The intra-patient viral population is a 
highly dynamic system, characterized by a high turnover and high mutation rate (Domingo et 
al., 1997; M. Nowak et al., 2000). HIV-1 replicates at a high rate in untreated patients, with at 
least 10
10
 new virions produced and cleared per day (Perelson et al., 1996). HIV-1 reverse 
transcriptase lacks proof-reading capability, so the mutation rate is high (1 in 10
4
 to 1 in 10
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nucleotide mutations per replication cycle, or about one mutation per newly produced viral 
genome) (Coffin, 1995; Mansky et al., 1995). This ability of HIV-1 to adapt to potent drug 
pressure was clearly shown in the studies of nevirapine and maternal-fetal transmission; a 
single dose of nevirapine given at the time of delivery was sufficient to select for a dominant 
virus population with genotypic drug resistance (Jackson et al., 2000). The virus population 
present at a certain time point within an infected individual consists of a complex mixture of 
heterogeneous strains (quasispecies) (Meyerhans et al., 1989). The quasispecies continuously 
compete among themselves and for survival and propagation (Fisher et al., 1988). The 
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subsequent overgrowth or dominance of a certain viral strain over another is largely 
determined by its relative adoption to its intra-host environment, a factor particularly relevant 
to the emergence of drug resistance virus variants. These evolutionary dynamics are the basis 
for a diversified population that can quickly generate drug resistance variants in response to 
the therapy (Metzner et al., 2013; M. A. Nowak et al., 1997). If viral mutations are associated 
with HIV drug resistance, these viral variants can have selective advantage and avoid drug 
pressure (Ho et al., 1995; Preston et al., 1988; Wei et al., 1995). Several studies have shown 
that low adherence is associated with increased risk of resistance emergence (Bangsberg et al., 
2003; Harrigan et al., 2005; Parienti, Massari et al., 2004; Sethi AK et al., 2003). Treatment 
interruptions of 2 or more days predicted resistance mutations in Uganda (Oyugi, Byakika-
Tusiime et al., 2007). In 2013, a study in South Africa showed that 6% of patients had a least 
one drug resistance mutation.  
Transmitted drug resistance does not result only from transmission after therapy failure in 
chronic patients but can be driven by on-going transmissions, if the resistant strain is fit 
enough for transmission and if the mutation(s) persists in the absence of drugs(Frange et al., 
2012; Yerly et al., 2009). A transmitted virus which harbours the K103N mutation, is able to 
persist without drug pressure (Gianotti et al., 2005) and K103N which is associated with 
resistance to Efavirenz and Nevirapine, two drugs that are widely used and recommended in 
first-line therapies. 
HIV-1 mutations associated with drug resistance are classified as either primary (major) or 
secondary (minor). Primary mutations are selected under drug pressure, may lead to a 
decrease in sensitivity to one or more antiretroviral drugs, and are extremely rare in the 
absence of treatment (Hirsch et al., 1998). Secondary mutations are defined as having little or 
no effect on drug susceptibility, but may lead to increased resistance or increased replication 
capacity in the presence of major mutations (Erickson et al., 1999; Hirsch, Conway et al., 
1998). The prevalence of HIVDR among ART-naive people in the USA and Europe has been 
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estimated to be 10%-15% (Simen et al., 2009; Wittkop et al., 2011).  In SSA, HIVDR was 
reported to be less than 5%, with growing evidence of increasing levels of resistance (Hamers 
et al., 2010; Manasa et al., 2012; Price et al., 2011). Studies in SSA demonstrated that the 
prevalence of resistance associated mutations (RAMs) in patients failing first-line ART 
ranged from 53 to 84% with 38 to 64% harboring dual-class resistance (Hamers et al., 2012; 
Hassan et al., 2014; Liegeois et al., 2012; Marconi et al., 2008).  
The International AIDS Society USA guidelines for the use of ART in adults recommend 
testing for HIVDR prior to initiation of therapy in high-resources countries (Hirsch et al., 
2008; Thompson et al., 2010). The WHO global HIVDR prevention and assessment strategy 
(Bennett, Bertagnolio, et al., 2008), which includes laboratory-based surveys of acquired 
(Jordan et al., 2008) and transmitted (Bennett, Myatt, et al., 2008)  HIVDR, monitors HIVDR 
Early Warning Indicators (EWI). EWI assess ART site and program factors potentially 
associated with HIVDR (WHO, 2010e). Utilizing data routinely collected in patients’ medical 
and pharmacy records, EWI monitoring is a minimum-resource strategy designed to be 
integrated into national monitoring and evaluation programs. EWIs survey factors related to 
patient care, patient behavior, and clinic-level and program management, all of which are 
associated with the emergence of HIVDR. When monitored annually at all or a large number 
of representative ART sites, EWIs provide countries with evidence to make programmatic 
adjustments at the level of an individual site or the country, when necessary. WHO updated 
their EWI definitions in 2012 (WHO, 2012). The baseline prevalence of HIV drug resistance 
in Kilimanjaro-Tanzania among HIV risk group (sex workers and bar maids) was estimated to 
be 7% (Kiwelu et al., 2014). Another study among HIV patients not eligible for ART 
initiation in Mwanza – Tanzania found the prevalence of RAM was around 18.2% (Kasang, 
Kalluvya et al., 2011). A study on patients eligible for ART initiation done in Kilombero 
Tanzania, found the prevalence to be 8.4% (Masimba et al., 2013). 
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1.5 HIV/AIDS management in Tanzania 
1.5.1 Tanzania National Aids control programme (NACP) 
The National AIDS control program (NACP) was established in 1987 under Ministry of 
health and social welfare with the overall aim of reducing incidence of HIV infection and its 
associated morbidity and mortality (TACAIDS, 2009a). The HIV/AIDS care and treatment 
plan was launched in October 2004 with the aim of providing quality care and treatment to all 
HIV infected patients in Tanzania. Access to ART has increased after then from 0.5% 
(NACP, 2013a) in 2004 to 65% in 2013 (NACP, 2013b) of patients in need. Patients with a 
CD4 count <350 cells/µl of whole blood, on WHO stage IV regardless of CD4 count and 
pregnant women with WHO stage III or IV regardless of CD4 + T cell count were eligible to 
start ART. Due to limited resources, a public health approach where by CD4 and WHO 
clinical staging are used to monitor HIV positive patients. The funding for the ART 
management in Tanzania is largely donor supported (95%) and major funding comes from the 
Global Fund for AIDS, TB and Malaria and the United States President’s Emergency Plan for 
AIDS Relief (PEPFAR) which contribute two thirds of the total donation (TACAIDS, 2008, 
February).  
1.5.2 Chronic Disease Clinic Ifakara (CDCI) 
The Chronic Diseases Ifakara (CDCI) started providing HIV care and treatment in Ifakara in 
2005. The observational open HIV cohort Kilombero and Ulanga Antiretroviral Cohort 
(KIULARCO) is managed and supervised by the Ifakara Health Institute (IHI) and the 
adjacent Saint Francis Referral Hospital (SFRH) (Mossdorf et al., 2011; Mossdorf et al., 
2010; Stoeckle et al., 2006). Since its opening, the CDCI has enrolled 6,500 HIV-positive 
clients, 3600 of which initiated ART as of July 2012. SFRH (formerly SFDDH) was the first 
rural District Hospital in Tanzania accredited by the National AIDS Control Programme to 
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become a Care and Treatment Centre at the end of 2004. Since then, uninterrupted VCT 
services and comprehensive care for an increasing number of persons living with HIV ⁄ AIDS 
have been offered at Ifakara (Stoeckle, McHomvu et al., 2006). During the study period, all 
patients with CD4 count <350 cells/µl of whole blood, patients with WHO stage IV regardless 
of CD4 count, and pregnant women with WHO stage III or IV regardless of CD4 count were 
eligible to start ART (NACP, 2008a; WHO, 2010b). Additionally, patients are required to 
come to the clinic with an adherence assistant who will help them to take their ART correctly. 
The patient has to visit the clinic on scheduled appointment or any time he/she feels a need to 
do so. 
2.0 CHAPTER TWO: Rationale, objectives and goals 
 2.1 Rationale 
There is a rapid scale up of ART for individuals with HIV in the developing world. The 
adoption of the public health guidelines to enhance ART programmes in Africa has led to 
treatment outcomes comparable to those attained in the Northern America and West Europe 
(Braitstein et al., 2006). The challenges observed in resource poor settings are access to ART, 
adherence issues and resistance associated mutations (RAM). All these factors limit the 
effectiveness of ART programs. There is a need to understand these parameters in Tanzania 
especially at a time when ART is being largely scaled up in rural settings. With this 
knowledge, the ministry of health and social welfare (MOHSW) may design appropriate 
strategies to reduce HIV associated morbidity, death and its associated cost to the health 
system. Being among one of the first CTCs to be introduced at the district level, serving two 
districts and caring and treating more than 6000 patients, the CDCI offers an excellent 
opportunity to address gaps in knowledge on supply management of ART, adherence to ART 
in rural TZ as well as risk factors associated with drug resistance. 
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2.2 Goal  
The goal of the study was to study supply of drugs, adherence patterns and drug resistance 
mutations so as to propose appropriate actions to improve the ART management in rural 
Tanzania. 
2.3 Objectives 
2.3.1. Main objectives 
 
1. Assessing the supply chain management for HIV/AIDS treatment in Kilombero and 
Ulanga districts. 
2. Study adherence levels of children and adolescents 
3. Identify the predictors of adherence among patients attending the CDCI 
4. Investigate factors associated with drug resistance associated mutations 
2.3.2. Specific objectives 
i. Assess the supply chain of HIV test kits and drugs in Kilombero and Ulanga CTCs 
ii. Evaluate key aspects of patient management such as functioning of laboratory 
              services, initiation and modification of ARTs and resources spent by patients’ to 
              access care in rural settings. 
iii. Describe the coping strategies of the CTCs and ART patients in times of stock-outs of  
             HIV test kits, cotrimoxazole and ART. 
iv. Investigate determinants for ART adherence and explore barriers and facilitators of  
             adherence among children and teenagers in rural Tanzania. 
v. Investigate the determinants of adherence among patients on ART attending CDCI. 
vi. Investigate risk factors for ART resistance mutations among patients attending CDCI        
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CHAPTER THREE: An assessment of supply chain 
management for HIV care in Kilombero and Ulanga districts 
 
ABSTRACT 
Background  
The Chronic Diseases Clinic Ifakara (CDCI) has been providing HIV care and treatment in 
Ifakara since 2005. Over time, several drug-refilling stations were created through the 
Tanzanian National AIDS Control Programme (NACP) to provide antiretroviral therapy 
(ART). Without any specific performance and outcome evaluation, these refilling stations 
were upgraded to comprehensive HIV care and treatment centres (CTCs). The objectives of 
this study were to evaluate the supply chain of the CTCs; key aspects of patient management 
and the coping strategies of the CTC staff and ART patients during stock-outs of drugs and 
test kits. 
Methodology 
In this cross sectional study, data were collected through structured interviews with staff in 
charge of 12 sites and patients on ART during un-announced visits.  Data was analysed using 
STATA 11.0. Hypotheses were tested using χ²-test for categorical variables and Mann-
Whitney U test for continuous data. 
Results 
All sites reported rapid test shortages to diagnose HIV. Seven CTCs (59%) experienced stock-
outs of cotrimoxazole drugs. The CDCI and all but one peripheral CTC reported stock-outs of 
ARV medication. CD4 + T cell count service and second line drugs were available at the 
CDCI and in two CTCs only. To cope with the stock-out situation CTCs staff had to stop 
testing for HIV, substitute the regimen depending on drug availability or closed the CTC 
temporarily. Patients coped by skipping ARVs and cotrimoxazole medications.  
Conclusion and recommendations 
Access to ART in Kilombero and Ulanga districts has some critical imbalances in the supply 
chain and management for HIV/AIDS care and treatment. Strategies to overcome the barriers 
are: (i) Routine data collection on ART supplies to estimate actual demand, (ii) Investments 
into mobile-health (m-health) for minimizing stock-outs problems, and (iii) more ART 
management training to be done on peripheral CTCs staff. 
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BACKGROUND 
Care and Treatment Centres (CTCs) to provide care and treatment to HIV patients were 
introduced in Tanzania through the National AIDS Control Program (NACP) in 2003 
(UNITED REPUBLIC OF TANZANIA, 2003). The NACP is integrated into the Tanzanian 
health care delivery system and HIV/AIDS care and treatment is based at the primary, 
secondary and tertiary referral levels (district, region, referral hospitals) (UNITED 
REPUBLIC OF TANZANIA, 2003). The Clinic for Chronic Diseases Ifakara (CDCI) in 
Kilombero district, was one of the first CTC to be established in Tanzania, and started 
providing ART since 2005 (Stoeckle, McHomvu et al., 2006). The CDCI is managed and 
supervised by the Ifakara Health Institute and Saint Francis Referral Hospital. Since its 
opening, the CDCI has enrolled 6,500 HIV-positive clients, 3600 of which initiated ART as of 
July 2012.  
The Voluntary Counselling and Testing (VCT) unit of the CDCI and CTCs routinely offered 
sequential rapid diagnostic tests (Mossdorf, Stoeckle et al., 2011) to establish HIV serostatus. 
As part of the efforts to decentralize HIV/AIDS care and treatment and to make antiretroviral 
therapy (ART) more accessible, several district level drug refilling sites were established in 
2009 through the NACP (TACAIDS, 2008). These drug refilling stations were originally 
designed to provide antiretrovirals in the periphery and refer critical patients to the next CTC 
available for further management, but were not entitled to initiate or modify ART. After two 
years and without any specific performance and outcome evaluation, they were upgraded to 
full CTCs. The upgrade from refilling stations to CTCs aimed at improving services and 
access to HIV patients and thus providing comprehensive care for patients at peripheral 
settings. These include ART initiation, treatment change and handling of more complex issues 
in HIV patient’s management. These changes were expected to save patient’s time and 
resources while improving the quality of care and patients’ quality of life.  
Thus, the original refilling stations are now operating as peripheral CTCs linked to the large 
ART-cohort at the CDCI. The CDCI has been supervising the former drug refilling stations in 
Kilombero and Ulanga districts from the beginning of their activities based on the NACP 
guidelines.  
The present study was undertaken to evaluate the overall situation of ART service delivery in 
the Kilombero and Ulanga districts within the context of central CDCI and upgraded refilling 
stations. The specific objectives were to (i) assess the supply chain of the CTCs, (ii) evaluate 
key aspects of patient management such as functioning of laboratory services, ART 
management and resources used by patients to gain access ART (iii) describe the coping 
29 
 
strategies of the CTCs and ART patients in times of stock-outs of HIV test kits, cotrimoxazole 
and ART.  
 
MATERIALS AND METHODS 
Study design, settings and participants 
This explorative and cross-sectional study was undertaken in September 2011 and involved 
CDCI and all 11 peripheral CTCs in Kilombero and Ulanga districts. The peripheral CTCs 
were in Lupiro, Mahenge, Mwaya, Mtimbira, Lugala, Itete, Mngeta, Mlimba, Kibaoni, 
Mang’ula and Ilovo as shown in Figure 1. Kilombero district is mainly a river plain with 
fertile alluvial soil while Ulanga is mountainous with some low-lying areas. The main 
economic activities of the population are subsistence farming and fishing (Masanja et al., 
2006).  
The study targeted the person in charge of the facility (CTCs or CDCI) and adult ART 
patients attending the CTCs/CDCI on the date of study visit or who attended recently in the 
case that no ART patients attended the clinic on study visit date. We interviewed every 
second patient to reduce selection bias as family members tend to attend clinic at the same 
time. Critically ill patients as determined by the respective physicians were excluded from the 
study.   
Data collection  
Semi-structured questionnaires were designed and piloted in two CTCs (Kibaoni and 
Mang’ula) and at the CDCI. Field interviewers were recruited, specifically trained and 
supervised during the entire data collection period.  
Interviews with person in charge of CTC aimed at establishing (i) the overall functioning of 
the CTC; (ii) the occurrence of stock-outs of HIV rapid test kits; (iii) possible coping 
strategies of health staff and clients during stock-outs of HIV rapid test kits; (iv) whether 
medicines were delivered in time; (v) the frequency, determinants and dynamics of ART 
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supplies and necessary drug changes and (vi) stock-outs experiences in the year preceding the 
study. In case of incomplete information, we visited respective sites up to three times to get 
the missing data. When ART patients were unavailable at the clinic, we had to visit them at 
their home with the help of a CTC staff.  
The patient interview included the following variables: place of residence, facility where CD4 
+ T cell count was analysed for the last time before ART initiation, changes in ART regime 
and the treatment centre where the changes took place, reasons for the changes, duration 
under ART, whether they ever stopped medication and transport and accommodation costs 
associated with treatment (cost information was collected in Tanzania shillings and later 
converted to US dollars at an exchange rate of 1600 TSH per dollar; rates September 2011).  
Data analysis 
Data were double-entered using EPI-DATA (EpiData Association, Odense, Denmark) and 
analysed using STATA 11.0 (STATA Corp., College Station, Texas, USA). The Shapiro-
Wilk test was used to test for normality. Statistical tools for hypothesis testing were χ²-test for 
categorical variables and Mann-Whitney U test for continuous variables that followed a non-
normal distribution.  
Ethical considerations 
The study was undertaken as part of the Kilombero and Ulanga Antiretroviral Cohort project 
(Mossdorf, Stoeckle et al., 2011) that received ethical and research clearance from the Ifakara 
Health Institute Institutional Review Board and the Medical Research Coordinating 
Committee of the National Institute for Medical Research. Research permit was granted by 
the Tanzania Commission for Science and Technology. All study participants provided oral 
informed consents. 
RESULTS 
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We managed to visit 11 CTCs and the CDCI for the interviews. The 11 CTCs in Kilombero 
and Ulanga districts were located between five and 150 kilometers from the CDCI. At the 
time of the study, the CTCs served between 48 to 700 HIV positive patients each. 
Participant’s characteristics 
A total of 89 ART patients (25 at CDCI and 64 at CTCs) were involved in the study (Table 1). 
In addition, 12 health care providers who were in charge of the CTCs and the CDCI were 
interviewed. At the CDCI the person in charge was a medical doctor and at the CTCs, five 
clinical officers and six nurses/midwives/assistant medical officers were included. All CTC 
staff, including those interviewed, had attended specific training for HIV care and treatment. 
Supply chain management of HIV test kits, cotrimoxazole and ART 
All responsible persons of the CTCs or CDCI interviewed reported to have experienced stock-
outs of rapid tests to diagnose HIV in the year preceding the study. CDCI and three CTCs 
experienced stock-outs of HIV test kits only once, five CTCs (42%) experienced stock-outs at 
least twice while three CTCs (25%) did not know how often stock-outs happened. The stock-
outs lasted for an average of 5.6 weeks (range: 1 week - 3 months). At the time of the survey, 
CDCI had both HIV diagnostic tests in stock while 5 (42%) and 3 (25%) CTCs did not have 
Bioline or Determine, respectively. An additional 3 CTCs (2 in Ulanga district) did not have 
any tests available at the time of the survey. The CDCI and 2 peripheral CTCs reported to get 
HIV test kits on time when ordered during stock-outs period, 7 of the CTCs reported that it 
took two or more weeks, 1 reported that it took 3 months to receive the HIV test kits once 
they were out of stock. 
CDCI and 36% (4/11) of the CTCs reported to have never experienced stock-outs of 
cotrimoxazole in the year preceding the study. Six patients (9.3%) at peripheral CTCs 
reported to have not taken cotrimoxazole tablets because of stock-outs. Among the patients 
who reported stock-outs of cotrimoxazole drugs in the peripheral CTCs, three of them 
experienced this once, two of them twice and one experienced stock-outs more than twice. Of 
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these six, three of the patients reported that the stock-outs lasted for more than one month; one 
patient reported that it lasted for one month and 2 patients reported the stock-outs lasted for 
one day. In the year preceding the study, CDCI and 91% (10/11) of the peripheral CTCs 
reported to have experienced ARV stock-outs in the past year. The only site that never 
experienced insufficient supplies was the Kibaoni CTC at the administrative centre of the 
Kilombero district. Two out of 64 patients reported to miss their ARVs, one because of stock-
outs at the nearest CTC and the other person ran out of pills.  
The CDCI and 36% (4/11) of the peripheral CTCs reported not to receive drugs in time in the 
year preceding the study due to delays in delivering after an order was posted. The peripheral 
CTCs mentioned that (i) there was no one responsible for ordering at the clinic (ii) they were 
late in ordering drugs (iii) there was a poor transport chain or (v) there were no drugs at the 
distributor’s site.  
Key aspects of patient’s management 
Functioning of laboratory services (point of care CD4 services) 
During the study period, CD4+ T cell count analysis was only processed at the CDCI and in 2 
CTCs (Mahenge and Lugala). In the Kilombero district, patients from other CTCs had to 
travel to CDCI for CD4+counts. In contrast, blood samples of patients in Ulanga district were 
brought to Mahenge and Lugala CTCs or CDCI for the CD4 + T cell count analysis.  
Drug (ARV) management 
Among 20 patients interviewed at the CTCs who reported to have changed their ART 
regimen, 17 (85%) of them had their drug modified at the CDCI while drug modifications of 
the remaining 3 (15%) were done at the CTCs. All patients who were interviewed at the CDCI 
reported to have had that their drugs modified at the CDCI. Forty percent of peripheral CTCs 
patients whose drugs were modified came from just three CTCs (Mahenge, Mlimba and 
Mngeta). Staff in charge of one CTC reported to have stopped ARV medication in a patient 
with multiple organ failures (kidney and liver failure). 
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According to patients at the peripheral CTCs, the main reasons for modifying ARV regimens 
were side effects (70%), stock-outs (15%), clinical decisions (10%) and pregnancy (5%). The 
main reasons stated by the health worker in charge of the CTCs were side effects (82%), 
pregnancy and co-infection with tuberculosis and other diseases (63%), stock-outs (45%) and 
clinical decisions (18%) (Multiple answers were common). Two patients at CTCs (3%) 
reported to have decided on their own to stop their medication in the past because of side 
effects. None of the patients interviewed at CDCI/CTCs was ever recommended to stop the 
ART drugs for any reasons by an ART clinician.  
Personal expenditures associated with ART 
Although care and treatment of ART patients are free of charge, there are costs associated 
with the treatment, particularly for transport and accommodation when having to visit CDCI 
or CTCs. There were significant differences in costs incurred between seeking health care in 
CTCs and CDCI. Visiting a peripheral CTC costed US$ 8.7 less on transport and US$ 5.3 less 
on accommodation. It took three hours less to reach the CTC than the CDCI as shown in 
Table 2. 
Coping strategies 
The CTCs, CDCI and patients had adopted several strategies to cope with stock-outs of HIV 
test kits and medicines. Apart from stopping HIV tests, they also changed the drug regimen 
while still maintaining triple therapy, temporarily closed the CTC and suspended taking 
medication. One and six patients stopped taking ARVs and cotrimoxazole, respectively after 
they were told of stock-outs during their clinical visits. The CDCI and 7 peripheral CTCs 
(64%)  reported to have stopped HIV testing when they were out of stock of test kits, 2 CTCs 
(17%) reported to post orders, while 1 (8%) reported the information to local authorities to 
inform them about the situation. Staff in charge of one CTC did not know what was done after 
the stock-outs. 
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In case of stock-outs of ARV drugs at the CDCI, communication was made with the nearest 
CTC (Kibaoni) for locally of sharing of ARVs treatment is changed while still maintaining 
triple therapy. In the peripheral CTCs, patients were referred to another CTC (if on second 
line, the patients were referred to CDCI), or they were told to come back when drugs were 
available or changed to alternative regimens within the first line while maintaining the triple 
therapy. One CTC reported to shut down the CTC office during the period of stock-outs. 
DISCUSSION 
This cross-sectional study done in Kilombero and Ulanga has found stock-outs of HIV test 
kits and ARVs is common. There is also a limited access of second line and CD4 point of care 
machine and coping strategies that actually create additional problems. 
Because knowledge of one’s HIV status is the entry point for all HIV care and treatment 
services, stock-outs of HIV testing kits have major impact on the effectiveness of the HIV 
control program particularly with respect to access to and retention in care.  All sites visited 
had experienced stock-outs of HIV test kits in the year preceding the study. There was a 
countrywide (Tanzania) stock-out of HIV test kits for several months in 2011. An assessment 
of lower level health facilities in Tanzania preceding the introduction of HIV/AIDS care and 
treatment reported that more than 90% of facilities did not have adequate laboratory supply 
chains for laboratory materials (NACP, 2009).  The main goals of programmes aiming at 
reducing HIV incidence may not be achieved as long as stock-outs of HIV test kits prevail. 
Stock-out of test kits and drugs has been reported to also affect other HIV programmes 
including Prevention of Mother to Child Transmission (Aavitsland et al., 2002; Gamell et al., 
2013), HIV screening for blood transfusion and VCT. As more people remain unaware of 
their serostatus because of lack of HIV tests, there will be an increased risk of infecting other 
individuals with the deadly virus (Hall et al., 2012). Careful monitoring, surveillance and 
comparative analyses will reveal to what extent stock-outs impact global HIV dynamics.  
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Stock-out of cotrimoxazole was common in the study area. WHO recommends provision of 
co-trimoxazole prophylaxis as long as CD4 cell count <350cells/ml, during pregnancy and in 
children born to HIV positive mothers (NACP, 2008b). Cotrimoxazole is a highly cost-
effective approach to reduce mortality among patients who present with advanced HIV at 
ART initiation and it also yields benefits for people with opportunistic infection (Abimbola et 
al., 2012). Randomized trials that included ART-naive Africans found that cotrimoxazole 
improved survival while reducing the risk of malaria, pneumonia, sepsis, isosporiasis, 
toxoplasmosis encephalitis and wasting (Anglaret et al., 1999; A. J. Nunn et al., 2008; Wiktor 
et al., 1999). Stock-outs of the drug, resulting in a higher number of HIV patients developing 
opportunistic infections (Sethi et al., 2003), may further accelerate HIV disease progression 
(Nischal et al., 2005), increase hospital admissions (Mulenga et al., 2007) and increase both 
health care costs  (McDonnell et al., 2002) and mortality rates (Wood et al., 2003) among 
HIV patients. 
All but one peripheral CTCs experienced stock-outs of ART drugs. In many low- and middle- 
income countries, the capacity of the procurement and supply management systems has 
always been weak (Pasquet et al., 2010). A WHO survey in 2009 revealed that 38% of 
countries had documented at least one stock-out of antiretroviral (ARV) drugs in health 
facilities (WHO, 2010d). Stock-outs of ARVs directly affect adherence to antiretroviral 
therapy (Weidle et al., 2006) which in turn increases the risks of resistance development, 
disease progression (Oyugi, Byakika-Tusiime et al., 2007) and mortality (Garcia de Olalla et 
al., 2002). A study conducted in northern Tanzania revealed that stock-outs led to no/few 
drugs being dispensed to HIV patients (Lyimo et al., 2012). Stock-outs of ARVs for the 
PMTCT programme mirror the general health system inadequacies within which the PMTCT 
programmes are implemented as reported in other African countries (Nkonki et al., 2007). 
Interestingly, a report of NACP preceding care and treatment  scale up found that only one 
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third of 553 lower level health facilities had a tracking system for ARVs in place and has 
sufficient storage space for a one month stock of ARVs (NACP, 2009).  
Patients from the three sites (Mlimba Mngeta and Mahenge) had a higher proportion of drug 
changes which might have been attributed by the long distance from the supply site and thus 
have drug delays and shortages, hence are forced to send their patients to CDCI where 
changes are prescribed. A decrease in ART coverage has been associated with a proportional 
increase in HIV incidence among HIV uninfected adults (Hontelez et al., 2013). With the 
stock-outs of ART, fewer people will be under ART and we should expect a relatively higher 
HIV incidence among uninfected people.  
Some coping mechanism adopted by the sites studied appeared to create additional problems. 
Closing temporarily the CTC might discourage clients from testing and thus increase the 
proportion of HIV positive people who are not aware of their status. A study conducted in 
Iringa region showed that some clients gave up testing completely after being turned away 
after stock-outs of HIV test kits, (Layer et al., 2014). A study in Zimbabwe revealed priorities 
were focused on PMTCT during times of HIV stock-outs (Kranzer et al., 2014). In some 
settings to cope with stock-outs, staff did dispense few pills so that many ART patients can 
get at least some (Lyimo et al., 2011). This option should be discouraged as it will likely lead 
to ART resistance mutations and treatment failure (Clavel & Hance, 2004; Tang et al., 2012). 
CD4 + T cell count analysis was done in very few sites in Kilombero and Ulanga districts. 
The reasons besides costs include a lack of skilled laboratory staff; the inability to maintain 
machines and/or assure reliable data; difficulties in managing the supply of reagents and a 
lack of adequate quality assurance schemes to ensure reliable results (Birx et al., 2009). 
Absence of point of care CD4 + T cell count may delay staging of HIV patients on site and 
thus increases the possibility of loss to follow-up (Jani et al., 2011).  
Our study had several limitations. Firstly, the study had to rely on estimates of the staff in 
charge of the CTCs if the information required was not documented or unavailable. Secondly, 
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the study had also a small number of ART patients and thirdly, and we did not ask follow-up 
questions such as on how many patients who were referred to another CTC for drugs actually 
went there. Nevertheless, our study has several strengths. The survey was unannounced, 
patients were randomly selected and staffs in charge of the CTCs in the region and the CDCI 
were included. Based on the fact that all CTCs in Tanzania have the same source of drug, we 
are confident that the study possessed internal validity and can be generalized to reflect 
situation in other peripheral CTCs in Tanzania and in other resource limited countries.  
In conclusion, access to ART in Kilombero and Ulanga districts has some critical imbalances 
in the supply chain and management for HIV/AIDS care and treatment. Potential strategies to 
overcome these barriers and improve the functioning of CTCs in harmonization with the 
central CDCI should be considered by the NACP and the district health teams. Our study 
suggests the following: (i) Routine data collection on HIV test kits and drugs supplies to 
estimate the actual demand and early ordering of the items, (ii) Investments into mobile-
health (m-health) by a targeted use of mobile phones for supervision and reducing stock-out 
problems in analogy to “SMS-for-life” in malaria (World-Bank) and (iii) more ART 
management training to be done on peripheral CTCs staff with special emphasis on how to 
handle second line drugs and complicated cases at their sites. 
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Table 1 Participants characteristics 
         CTCs CDCI 
  n % n % 
No of patients 64 72 25 28 
Sex 
 
  
 
  
  Male 21 32 13 54 
  Female 43 68 12 46 
District 
 
  
 
  
  Kilombero 35 55 23 92 
  Ulanga 29 45 2 8 
Where CD4 analysed before 
ART initiation         
  CDCI  31 48 21 84 
  Others 33 52 4 16 
Incurred transport cost 
 
  
 
  
  Yes 26 41 16 64 
   No 38 59 9 36 
Incurred accommodation 
cost 
 
  
 
  
  Yes 1 2 20 80 
  No 63 98 5 20 
Duration on ART in yrs 
(mean) 1.8 (1.3-3.2) 2.2 (1.1-3.3) 
CTC: Care and treatment centres at peripherals, CDCI: Chronic Diseases Centre Ifakara, yrs: 
years 
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Table 2: A table showing resources used to get access to the CDCI and CTCs 
  CTC CDCI   
  
Median (IQR) 
N Median (IQR) N 
P-
Values 
Transport cost (US $) 
1.3, (0.6-1.9), 
26 
10, (6.3-12.5), 
15 <0.001 
Accommodation cost* (US $) 1 
6.3, (1.9-6.9), 
20 NA 
Travel time (hours) 1, (0.5-2), 42 4, (3-5), 23 <0.001 
*P-value for accommodation cost could not be calculated as there was no standard deviation 
because only one patient had incurred accommodation cost while attending peripheral CTC. 
Transport cost included go and return fares from home to CTCs.  Cost were collected in 
Tanzanian shilling and later transformed to US $ 
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Figure 1 Map of Kilombero and Ulanga showing CDCI and CTCs 
 
 
NB; There are 6 CTCs (including CDCI) in Kilombero district and 6 CTCs in Ulanga district 
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CHAPTER FOUR: ART adherence to HIV positive children and 
adolescents 
ABSTRACT 
Background 
Around 3.3 million children worldwide are infected with HIV and 90% of them live in sub-
Saharan Africa. Our study aimed to estimate adherence levels and find the determinants, 
facilitators and barriers of ART adherence among children and teenagers in rural Tanzania. 
Methods 
We applied a sequential explanatory mixed method design targeting children and teenagers 
aged 2-19 years residing in Ifakara. We conducted a quantitative cross sectional study 
followed by a qualitative study combining focus group discussions (FGDs) and in-depth 
interviews (IDIs). We used pill count to measure adherence and defined optimal adherence as 
>=80% of pills being taken. We analysed determinants of poor adherence using logistic 
regression. We held eight FGDs with adolescent boys and girls on ART and with caretakers. 
We further explored issues emerging in the FGDs in four in-depth interviews with patients 
and health workers. Qualitative data was analysed using thematic content analysis. 
Results 
Out of 116 participants available for quantitative analysis, 70% had optimal adherence levels 
and the average adherence level was 84%. Living with a non-parent caretaker predicted poor 
adherence status. From the qualitative component, unfavorable school environment, timing of 
the morning ART dose, treatment longevity, being unaware of HIV status, non-parental 
(biological) care, preference for traditional medicine (herbs) and forgetfulness were seen to be 
barriers for optimal adherence.  
Conclusion and implications  
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The study has highlighted specific challenges in ART adherence faced by children and 
teenagers. Having a biological parent as a caretaker remains a key determinant of adherence 
among children and teenagers. To achieve optimal adherence, strategies targeting the 
caretakers, the school environment, and the health system need to be designed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
44 
 
BACKGROUND 
At the end of 2012, an estimated 35.3 million [32.2–38.8 million] people were living with 
HIV. The UNAIDS global report 3.3 million children had HIV globally, 2.9 million in sub-
Saharan Africa (UNAIDS, 2013c). In 2012, there were 230,000 children living with HIV and 
1.3 million orphaned by AIDS in Tanzania (UNAIDS, 2012c). Treatment of HIV infected 
patients with ART has resulted in a dramatic reduction in HIV related morbidity and mortality 
(WHO/UNAIDS/UNICEF, 2011). Successful treatment results in virological suppression, an 
increase in the CD4+ T cells count, and improvement in the clinical well-being of the 
individual, manifesting as weight gain and resolution or control of opportunistic infections 
(Paintsil, 2011). Adherence to treatment regimens is a prerequisite for the efficacy and 
durability of any ART (Harries et al., 2004; Paterson et al., 2000). According to recent 
studies, ART regimens require 70–90% adherence in order to be effective (Nachega, Mills et 
al., 2010). Some studies show that viral suppression for patients treated with non-nucleoside 
reverse transcriptase inhibitors (NNRTI) is possible with adherence levels ranging from 54%–
100% (Bangsberg, 2006).  Poor adherence to ART regimens results in incomplete suppression 
of HIV replication and emergence of resistance to ART that increase the potential for 
treatment failure, compromising future treatment options and leading to increased risk of 
mortality (World Health Organization, 2006). The World Health Organization (WHO) 
recommends regimens involving tablets and that syrup or liquid formulation be prescribed for 
children depending on weight, however recognizing that lack of refrigeration and the supply 
chain for syrup or liquid forms may bring some challenges (World Health Organization, 
2010). Children and adolescents with HIV often face other life stressors that affect their 
ability to achieve optimum adherence, including parental HIV disease, poverty, and limited or 
inconsistent social support (Steele et al., 2007). Availability of adherence information assists 
health care workers in providing optimal care to patients.  
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In Tanzania, studies on adherence have been primarily focused on adults and less information 
is available on children and teenagers. As children form a special group due to lengthy 
expected time on ART and challenges faced during adolescence, more information is needed 
in order to design appropriate interventions to improve or maintain sufficient ART adherence 
levels. This study estimated adherence levels, investigated determinants for ART adherence 
and explored barriers and facilitators of adherence among children and teenagers in rural 
Tanzania.                
METHODS 
Study design 
We used a sequential explanatory mixed methods study design. A quantitative cross sectional 
study was followed by a qualitative study combining focus group discussions (FGDs) and in-
depth interviews (IDIs).  
Study setting 
We conducted the study in Ifakara town in the Kilombero district of the Morogoro region for 
6 months between November 2011 and April 2012. The study was performed within the 
observational HIV cohort, Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), at the 
Chronic Diseases Clinic Ifakara (CDCI) in St Francis Referral Hospital (SFRH). The CDCI 
started providing HIV care and treatment in 2005 in Ifakara (Mossdorf, Stoeckle et al., 2011; 
Mossdorf, Stoeckle et al., 2010; Stoeckle, McHomvu et al., 2006) in accordance with 
guidelines of the Tanzanian National AIDS Control Program (NACP) (National Aids Control 
programme, 2005). Follow up visit are scheduled every 3-6 months. All patients were treated 
as per Tanzania National Guideline for HIV/AIDS treatment (NACP, 2008b). During the 
study, liquid formulations were only available for prophylaxis among HIV-exposed infants 
and not as treatment for HIV infected children. Early infant diagnosis (EID) was unavailable 
at CDCI during the study period but has been recently introduced. 
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Quantitative component 
Study participants  
We targeted all patients attending the CDCI who were on ART and aged between 2-19 years. 
Patients were included if they had visited the CDCI for a drug refill between 10-150 days 
prior to the start of the study. The study participants were traced and interviewed at home 
during an unannounced visit. For the quantitative data collection, children below 18 years 
were interviewed together with their parents/caretakers. We did not interview children who 
were critically ill.  
Data collection 
The interviews were conducted in Swahili, the national language of Tanzania and commonly 
spoken by Ifakara residents. For the quantitative study, data were collected by trained non-
medical field interviewers using a structured questionnaire.  
Variables 
Outcome 
The primary outcome variable was ART adherence. Percentage adherence was measured as 
the ratio of drugs actually taken to the drugs supposed to be taken (prescribed) by using the 
formula [Adherence= (Number of pills dispensed - Number of pills remained) ×100)/ 
(Number of pills prescribed per day × number of days between pharmacy visit and home 
visit)].  The drugs actually taken were estimated by calculating the number of dispensed drugs 
minus the drugs found during the unannounced visit. This was assessed using pill count, 
which was first calculated by field worker and then verified by a field manager. The overall 
average adherence was calculated in two steps. Since commonly used ART regimens involve 
a combination of three drugs and are dispensed as either a fixed dose or a separate 
combination, the adherence percentage level for each drug was calculated. Then the average 
adherence for each regimen was assessed for each individual. Participants were encouraged to 
provide all ART pills that were dispensed at the clinic in the last visit plus the ones that 
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remained from the prior visit. For individuals whose adherence levels exceeded 100%, the 
adherence level was capped at 100%. For the analysis, optimal adherence was defined as 
having taken >=80% of the required pills.  
Predictors of ART adherence 
The determinants for ART adherence were : gender, pill burden, visit to a local healer (who 
claimed to have a cure for HIV/AIDS), disease progression measured by age-specific 
immunological criteria (immune-suppressed if CD4 <500 cells/mm
3
 for children aged <6 
years and if CD4<350 cells/mm
3
 for children ≥ 6 years) and WHO clinical staging (I/II versus 
III/IV), child awareness of HIV disease, parental status (both parents, single parent, or non-
parental caretaker (non-parental caretaker included patients grandmother, sister, aunt, uncle or 
step mother)), distance to the clinic, duration under ART, knowledge about ART treatment 
duration, HIV support group membership, adherence assistance (parents versus others), 
socioeconomic status (SES) and education level. Education level was assessed by combining 
age and school attendance (preschool age (2-5 years), children of school age (6 years or more) 
who never went to school, children of school age and in school, children of secondary school 
age (12 years or more) but in primary school, and children of secondary school age and in 
secondary school). 
Collection of socioeconomic status (SES) data 
Data on socioeconomic status was collected using an asset survey from June 2011 to 
September 2011 among 1935 patients under ART enrolled in KIULARCO. ‘Low’, ‘middle’ 
and ‘high’ tertiles of socio-economic status were constructed using principal component 
analysis (Nikoi et al., 2013) on scores calculated from asset ownership (electricity, lamp, 
radio, television, mobile phone, land line, iron, refrigerator, wrist watch, bicycle, motor bike, 
motorcar, and having a bank account) and the house’ building materials (mud, bamboo, wood, 
tiles, cement, carpet, grass, post, brick (sun), brick (fire), wood, cement bricks, iron sheets, 
tiles, concrete and fabricated bricks).  
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Bias 
Classification bias of adherence level was minimized by training field interviewers on how to 
assess and calculate adherence percentages as well as cross-checking adherence estimates for 
confirmation by a field manager before data entry. To reduce social desirability bias, 
information on level and determinants of adherence was collected by non-medical staff.  
Sample size 
We included all active patients aged 2-19 years under ART attending the CDCI within the last 
150 days, i.e. 163 patients. Using an alpha of 5%, a power of 90% and a hypothesized 
adherence prevalence of 70% in the reference category, with this effective sample size we 
were able to statistically significantly detect a risk ratio of 1.4. 
Data processing and analysis 
Quantitative data were double entered using EPI-DATA (EpiData Association, Odense, 
Denmark) and analyzed using STATA 11.0 (STATA Corp., College Station, Texas, USA). 
Chi square test was used to assess the association between the variables studied and the 
response status and with the adherence categories. Logistic regression was used to estimate 
associations between adherence and risk factors. Participants with missing adherence 
(outcome) data were excluded from analysis. Sensitivity analyses were done to assess the 
potential influence of missing values for predictor variables. Variables with a P-value of less 
than 0.25 were eligible for inclusion in the multivariable analysis. Since this applied to only 
one variable (parental status), we reported only the univariate analysis. We assessed if non-
response was associated with variables under the study. Variable(s) that were found to predict 
adherence were investigated in the qualitative part to understand the mechanism underling 
such association.  
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Qualitative component 
Population and Sample 
We targeted adolescents aged 13-17 years who were on ART who were aware of their HIV 
status and the parent or non-parent caretakers in charge of the child. The Tanzanian definition 
of adolescents has been adopted from the WHO (World Health Organization, 2014) which 
defines adolescent as a young person aged between 10-19 years.  However, for the purpose of 
this study, we interviewed adolescents of age 13 to 17 years assuming that these adolescents 
will be capable of expressing their views on issues related to treatment experience and 
challenges. From the CDCI database we randomly sampled boys and girls aged 13-15 and 16-
17 and within each group conducted one FGD. In total we included 35 HIV infected 
adolescents in the FGDs.  We also conducted FGDs with 21 parents or caretakers living with 
HIV infected adolescents (on ART) residing within the study site, two FGDs with women and 
two with men. Each FGD comprised of 7-8 participants. We opted for the FGDs due to their 
usefulness in enhancing social interaction different from other qualitative methods (Merton et 
al., 1990), high face validity (Krueger, 1988) and their relevance in providing opportunity to 
interview several participants systematically and simultaneously (Babbie, 2011). To deepen 
our understanding of issues emanating from FGDs, we subsequently conducted four IDIs, 
with a 16 year old male patient, a 43 year old male caretaker of an eight year old child and 
with two healthcare providers (a medical doctor and a nurse). 
Data collection 
An interview topic guide with specific themes aided the FGDs. The was guide composed of 
broader themes that relate to attitude and perception on ART, perceived benefit of ART 
treatment, perceived risk of treatment, knowledge about treatment adherence, family 
strategies to ensure treatment adherence, children’s experience with treatment and perceived 
barriers to treatment adherence. Interview topics were drawn from the relevant literature (Li et 
al., 2010), health behavior theories (Ajzen et al., 1980; Rosenstock, 1966) and life 
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experience/observation. The second author who is a female social scientist facilitated the 
discussions aided by a trained male research assistant. To enhance freedom of expression 
during FGDs, participants’ were facilitated by researchers of matching sex and in a neutral 
venue, i.e. at a school after school hours. The discussions were audio recorded following 
permission from the participants. Throughout the interview, free flowing discussion was 
encouraged and some new topics which were raised in the first interview were again probed in 
the next interviews following the principles of grounded theory (Ajzen & Fishbein, 1980). 
Unlike adults, children’s explanations about barriers to treatment adherence were in short 
segments, sometimes not very direct but useful. The researcher took time to probe and 
motivate children to provide their inside views and experience that relates to taking the 
lifelong treatment.  
Data Analysis 
After the interviews, the research assistants transcribed verbatim digitally audio recorded 
interviews in Swahili language. The second author frequently reviewed the transcripts using 
the side notes and relevant ideas were noted. Thematic content analysis was used to process 
all participants’descriptions along with identification of relevant concepts and ideas found in 
the transcripts linked to the topics of inquiry (Anderson, 1997).  
Relevant ideas were categorized under specific themes and later coded (LeCompte et al., 
1994). We included the pre-existing themes, for example “attitude towards ART treatment” 
and “non-parental care”. We also included emerged themes such as “supportive school 
environment” and “unfriendly nature of counseling services”.  
Ethical statement 
The study received ethical clearance from National Institute of Medical Research of Tanzania. 
Parents and caretakers signed the informed consent to participate in the study, both for 
themselves and on their children’s behalf.  Participating children assented to answer 
questions. Records were anonymized and patients were identified by unique identifiers during 
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analysis and reporting. As per routine procedures in the clinic, patients who had poor 
adherence levels were further followed up by physicians in the CDCI. 
RESULTS  
Data flow 
There were 265 HIV patients <20 years of age attending the clinic of whom 163 (62%) were 
currently on ART (Figure 1). Forty patients (25%) were not interviewed because of refusal, 
non-availability or death. The reasons for non-availability were undocumented transfer, an 
incorrect home address or travel of the patient. For the quantitative study, we interviewed 123 
(75%) of 163 patients approached. Among the patients successfully interviewed, seven were 
excluded from the analysis because they did not have adherence data (they did not provide 
their pills during the home visit). We finally included 116 children and adolescents in the 
analysis (Figure 1). Non-response was not associated with the variables under study (Table 3).  
Study participants characteristics 
Sixty-seven (58%) of the participants were males. The median age was 9.8 years (interquartile 
range (IQR): 5.7 – 13.3, range 2 - 19), and 77 (66%) of the participants were not living with 
both parents (out of these, 61% (47/77) were not living with either parent). Patients had been 
taking ART for a median of 35.8 months (IQR: 23-46) (Table 3). All participants were taking 
first line treatment regimens based on 2 NRTIs+1 NNRTI.  
Adherence levels  
The overall average ART adherence level was 84.2% with a range from 2.3% to 100% and 
the proportion of patients with adherence level of 80% or more was 70% (81/116).  
Determinants for adherence 
From the logistic regression analysis, children living with non-parent caretakers were more 
likely to have poor adherence compared to children living with their parents ((OR=2.84, 95% 
CI: (1.04-7.77)) (Table 4). Children living with single parent or non-parent caretaker had 
lower levels of optimal adherence compared to children living with biological parents. The 
52 
 
magnitude of association between adherence and educational status was high, but the 
evidence of association was statistically non-significant (children of primary school age (6 
years or more) who never went to school compared to preschool age children, OR=2.39, 95% 
CI: (0.69-8.28)). Children who reportedly joined an HIV support group had a lower 
proportion of optimal adherers compared to children who were never members (OR =2.0, 
95% CI 0.75-5.27). The quantitative analysis showed no associations between adherence 
levels and sex, education, duration on ART, CD4+ T cells count, WHO clinical staging, SES, 
ever visited traditional healer, pill burden and disclosure status. 
Barriers and facilitators of adherence 
The results of the FGDs and IDs complemented the cross-sectional survey and shed further 
light on its findings. The thematic analysis suggested a range of themes influencing adherence 
to ART, many of which were commonly shared among the FGD and IDIs participants. 
Facilitators of treatment adherence 
Positive attitudes and perceived benefits towards treatment 
Both children and caretakers reflected a positive attitude towards treatment. This was 
indicated by the adolescent’s expression of “feeling good with the treatment” which was a 
common statement by most of the children. Caretakers shared the same experience “we 
become happy when we see health improvement of our children”.  
Positive attitude towards treatment was also reflected by the experiences reported by the 
groups in relation to the perceived benefits of treatment. The most recurrent themes related to 
the perceived benefits of treatment included the ‘reduction of recurrent diseases’, “looking 
healthy after the initiating ARV”, “living longer”, “getting cured”, “ability to participate in 
economic activities” and “ability to attend classes”.  
The following excerpts indicate some of the related themes:  
“My son used to be sick every day, and he was very thin, but after treatment initiation 
I can see that he is now well, but I can see other children also, before they start 
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treatment they become very sick but after treatment they change (their health status). 
[FGD, Female]. 
“Ooh, the treatment is good, like me I wasn’t like this, before taking this treatment I 
had rashes all over my body and I was so thin until my fellow children were avoiding 
me and said she has AIDS, but when I started taking the medicine, my condition 
changed and I am now big and healthy”. [FGD, Girl]. 
Knowledge about treatment adherence 
Generally, participants were able to explain the meaning of treatment adherence conditions. 
The most frequently mentioned treatment adherence conditions included “taking drugs in the 
morning and evening”, “taking drugs without stopping”, “taking drugs before food”, “eating 
fruits” and “abiding to the time of taking drugs without changing”.  
For those who were able to mention the risks of non-adherence to treatment, they mostly 
mentioned recurrence of illness, suffering and death as reflected in the following excerpts:   
“Following treatment instructions it means taking drugs every day because at times the 
body is used to that.  When you stop abruptly the body will get problems because it 
will notice the difference. And the body will get fevers which were over”. [FGD, 
Female].      
Treatment adherence barriers 
Despite respondents clearly valuing ART, several barriers existed for maintaining ART 
adherence in the social environment, in the health service delivery, and related to the 
treatment and disease itself. 
Fear of stigma and consequences  
Most caretakers and children were strongly opposed to sharing the child’s treatment status 
with other people, friends or relatives in the community due to fear of mocking by other 
people in the community. Most children and adolescents viewed taking their treatment pills in 
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front of their fellow children as unacceptable due to negative reaction from other children in 
the community: 
“I can’t dare to tell any of my friends or neighbors that my child is on treatment, 
because they will start spreading this information to others”. [FGD, Male]. 
“When I take these drugs they (other children) will say, “We do not know what  
he is suffering from. He is taking drugs every day; but he is not getting cured”. [FGD, 
Boy]. 
Enacted stigma also contributed to a lack of a supportive school environment. The school 
mates and teachers mocked, segregated and stigmatized children with HIV taking ART. Some 
children reported that they initially used to take their drugs at school but have decided to 
change and begin to take drugs at home due to some insults from their fellow students. 
Parents fear disclosing their children’s HIV and treatment status to teachers because “
of fear that their children may be segregated. My child was pinned a red label on his 
shirt by his teacher after he knew the HIV and treatment status of the child”. [FGD, 
Male]. 
“In the past fellow schoolmates started mocking at me that I have AIDS after they saw 
me taking ARV at school. Later I had to change and started taking the pills at home”. 
[FGD, Girl]. 
Non-parent caretaker 
According to the FGD discussants, children who live with their biological parents receive 
much more treatment support and care as compared with children who live with their 
caretakers. 
 “Step mothers contribute also to poor adherence. At times it happens that you are sick 
and the father asks the mother to take you to the hospital. When dad goes to work, the 
step mother doesn’t take me for treatment and I continue suffering”. [FGD, Boy]. 
Health service delivery factors 
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Some children and caretakers expressed their concern about the counseling sessions offered at 
the health facility which combined adults and children all together. Children felt that they 
need to have separate counseling sessions so they can express their treatment challenges 
freely without having adults interfering and can receive the attention they need from the 
counselors.  
“They combine us (children) with those (adults), when we are there with them (adults) 
we cannot understand things (information) and some of us cannot ask questions or 
explain problems…. There should be some separate sessions for children and so the 
doctors could listen nicely to children”. [FGD, Boy]. 
Not informed about HIV status 
Some children expressed their concern that they were not informed about their HIV status by 
their parents. One child described his concern as follows:   
“I grew up taking medicine without knowing the disease that I was suffering. They 
kept on telling me that I have malaria and until now they have not told me anything 
with regards to HIV, but the doctor told me that I am HIV positive and I feel bad that 
my sister did not tell me”. [FGD, Boy].  
Some parents also explained difficulties faced in disclosing HIV status to their children but 
once informed the children were able to adhere with their treatment schedule, as explained by 
one parent in the following excerpt: 
“I asked my child to take medicine without telling him what he was suffering from.  
When I told him what he was suffering from (HIV), it helped him to follow the 
instructions.  I told him that his mother died because of the same problem and that he 
should not stop taking drugs”. [FGD, Male]. 
Preference of Traditional medicine 
Some parents encourage their children to go beyond the formal health sector and take 
traditional medicine instead of drugs obtained at the health facility.  
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“Some parents do not want their children to take medicines from the hospital. They 
give them traditional medicines when it is obvious that the child has AIDS”. [FGD, 
Boy]. 
Inconvenient treatment schedule and longevity of the treatment (treatment fatigue) 
Taking drugs in the morning before going to school was not very patient-friendly as children 
often forget while hurrying for school or felt sick if they were forced to take drugs before 
breakfast. One boy expressed the concern as follows: 
“My mother tells me to take drugs in the morning and I sometimes wake up very early 
and no food prepared, and when I take medicine (in the morning) I feel nausea but I 
go to school just like that… and I try not to miss school…”. [FGD, Boy]. 
Children and caretakers gave the impression that some children are getting tired of taking the 
medications as explained below: 
 “Some grown-up children may sometimes cheat that they have taken drugs while they 
have not, because they are tired and the parents believe that they have already taken 
the drugs”. [FGD, Female].  
“Some children are tired of taking medicine, I remember one day when I was giving 
my child medicine, and he told me that, ‘uncle if you want to give me medicine give me 
even those for tomorrow’”. [FGD, Male].  
Forgetfulness and feeling better 
Patients FGD discussants from both groups mentioned the problem of forgetting to take drugs 
at the appropriate time due to the intensity of their engagement in games. At times, especially 
when patients observe some health improvement, they do not have the motivation to continue 
with treatment. 
“There are others (children) who put priority on games and when they are playing 
they forget to take drugs completely”. [FGD, Boy]. 
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“You find another person goes to the hospital and when they are given drugs they take 
them for one month and in the next month they stop taking these drugs when they see 
that they are OK”. [FGD, Girl]. 
DISCUSSION 
This explanatory mixed-methods study among children and teenagers attending a large HIV 
care and treatment clinic showed that participants had a positive attitude towards ART and 
70% of the participants achieved desired level of adherence (defined as 80% or higher). The 
proportion of patients with acceptable levels of adherence varies across several studies using 
different techniques of evaluating adherence. 
A review of ART adherence in low and middle-income countries found a range in adherence 
level estimates from 49% to 100% with 76% of articles reporting >75% adherence (Vreeman 
et al., 2008b).  A study done in India showed 95.3% (Seth et al., 2013) of the children had 
acceptable level of adherence whilst a study done in Dar es Salaam showed 97% (Mghamba 
et al., 2013) of children had optimal adherence. Another study done in Ethiopia showed that 
34.8% of the children had acceptable level of adherence when unannounced home visit was 
made (Biressaw et al., 2013). The wide difference here appears to be driven by the nature of 
the visits (announced versus unannounced or prior known visit).  Possible explanations for a 
low adherence in our study might be: (a) by interviewing participants at home, we might have 
captured children who were at risk of being “lost to follow-up”; in clinic-based studies these 
children would not have been included; (b) we used non-medical staff to collect information 
which may have reduced social desirability bias; (c) measuring adherence by pill count 
usually shows low adherence levels compared to other methods such as self-report (Martin et 
al., 2009) and lastly (d) our study participants had an average treatment duration of 3 years, 
and as the qualitative part outline treatment fatigue was present. 
Patients not staying with biological parents were more likely to have poor adherence. Other 
studies found that children’s adherence is affected by their dependence on caretakers and that 
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if adult caregivers are unavailable, the risk of missed doses increases (Marcus, 2006; 
Nabukeera-Barungi et al., 2007). The successful treatment of a child requires the commitment 
and involvement of a responsible caregiver yet qualitative findings showed that most often 
both parents and children are concerned with the stigma related to disclosure of HIV status to 
other family members or caretakers, friends and schools teachers thus restricting the child’s  
options for seeking support (World Health Organization, 2010). According to our participants, 
the care given to HIV infected children by biological parents was not the same as that given 
by non-parental caretakers.  This may be partly because some non-parental caretakers were 
unaware of the child’s HIV status. In other studies, disclosure was related to improved 
adherence to ART medications and influenced children’s participation in healthcare decision-
making (Bachanas et al., 2001; Bikaako-Kajura et al., 2006; Blasini et al., 2004; Lesch et al., 
2007). Health illiteracy might be another issue surrounding poor adherence levels. Compared 
to adults, children have lower levels of health literacy and thus, following health care 
providers’directives on maintaining adherence might not be easy for them (Marcus, 2006). 
In times when children focus too much on playing with friends, they tend to forget taking the 
drugs and the situation worsens if their caretakers are not present. Children who live with 
HIV-positive parents have the potential additional benefit of the parental experience in living 
with HIV and taking ART. However, we did not have information on the HIV status of 
parents or caretakers. Children with non-parental caretakers were older (median age 11.4 
versus 8.3 years) suggesting that some adherence problems might be partially attributed to 
puberty. However these possible explanations should be investigated further.  
Secondary school aged children who had only primary education or were still in primary 
school were more likely to be non-adherent, although the association was not significant. This 
may be partly explained by the fact that 50% of these children were living with non-parental 
caretakers, thus were at risk of less support to maintain adequate adherence levels. The 
study’s qualitative part provides another explanation for these findings. The morning dose 
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was challenging for children attending school as they often have to leave for school early in 
the morning before breakfast is ready. Competing demand between taking the morning ART 
dose and rushing to school make them vulnerable to skip their medications. A study on how 
food insecurity impacts on non-adherence to ART found that side effects were exacerbated 
when taking ART in the absence of food (S. D. Weiser et al., 2010). However, our study’s 
participants reside in a location where food supply is quite stable and food shortage was not 
reported as a barrier for optimal adherence in the qualitative component. It was rather the 
school environment where HIV patients experienced mocking and segregation which made it 
hard for them to take their ART while at school and led to missing the morning dose. In some 
settings HIV positive children attending school were given names by their colleagues so as to 
victimize them. In Namibia for instance, it was found that derogatory terms have been used to 
discriminate HIV students (Chinsembu et al., 2011). This impacts adherence levels as low 
social support (Halkitis et al., 2005) and stigma  has been identified in previous studies to 
affect access to health care, social interaction and medication adherence (Carr et al., 2004).  
The association between adherence and SES, although not significant, is in an unexpected 
direction; patients coming from affluent families are at higher risk of poor adherence. The 
effect of SES on adherence among HIV infected patients is considered a controversial issue 
(Fong et al., 2003; Goldman et al., 2002; Ickovics et al., 2002). Suggested pathways in which 
socioeconomic status might be associated with adherence include education's effect on 
shaping a financially stable future, and on acquiring health literacy and knowledge to use 
health resources, while income plays a big part in obtaining better housing conditions, 
recreational facilities and better health care (Adler et al., 2002). However, a systematic review 
of the evidence regarding the association of SES with adherence to treatment of patients with 
HIV/AIDS found no conclusive support for existence of a clear association between the two 
variables (Falagas et al., 2008). From the explanatory qualitative study, barriers of optimal 
adherence were unfavorable school environment, patients being unaware of their own HIV 
60 
 
status, children feeling too shy to go to collect medication at the clinic, parents’ failure to 
disclose the children’s HIV status to family members/caretakers and differential care from 
non-parental caretakers.  
Strengths and limitations of the study 
Apart from the strengths aforementioned, using a mixed methods design allowed explanation 
and in-depth understanding of the quantitative results. The patients were set in programmatic 
conditions i.e. not in a clinical trial cohort with intensive support. The study covered a wide 
time window, thus increasing generalizability and reducing potential seasonality bias. 
In addition to limitations of the methods used for measuring adherence, selection bias may 
have resulted from the rather high non-response rate of 25%. However non-response analysis 
showed that variables under study were not associated with non-response. In addition, we 
performed sensitivity analysis (data not shown) for predictor variables with missing 
information and the results were not considerably affected except WHO staging. However 
WHO staging was taken from the clinic database (and not the home visit) and was often 
missing due to drug refill visits by someone other than the patient. In some studies, pill count 
has been found to predict response to ART (Liu, Golin et al., 2001), particularly when 
conducted with no prior notification. However, in other studies, it has been shown to be liable 
to pill dumping (Feinstein, 1990), fabrication, and manipulation. Grouping a cohort of 2-19 
year olds together might have disguised specific adherence challenges for younger children 
(palatability, caregiver availability), which are very different from the challenges for 
teenagers. 
 Implications 
The implications of poor adherence for these children might be that they experience worse 
clinical outcomes. If this situation extends beyond our immediate setting, both the current and 
future treatment options are under threat if appropriate actions are not put in to place to 
address adherence issues in children and teenagers. A systematic review showed that almost a 
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quarter of patients fail second-line therapy within 12 months, mainly because of poor 
adherence rather than drug resistance (Ajose et al., 2012). As this age group (12+yrs) is 
becoming sexually active, the likelihood of transmission of HIV increases when the drugs are 
not taken properly and the virus is not suppressed (Cohen et al., 2011). New efforts have to be 
made and fully implemented to boost adherence to ART in this important population.   
The following recommendations could help improve adherence among children and teenagers 
in settings similar to ours: Parents and/or caretakers should counsel and guide children on 
taking drugs parallel with providing a supportive environment at home i.e. family supporter to 
ensure that during the parent’s absent children are able to maintain good adherence. 
Caretakers should create conducive environment at home for children i.e. make sure that food 
is ready before the child take his/her dose especially in the morning. Counsellors should 
improve counselling techniques and focus more on how to overcome challenges that make 
children not take their drugs as required. Furthermore, children should have age-specific 
counseling services at HIV clinics separate from adults. This can be done at the HIV clinic or 
at home during home-based care (HBC) visit. Assigned caretakers (parents or non-parents) 
should disclose their children’s HIV and ART status to household members who will be able 
to provide support to children when parents are absent. Health promotion messages should be 
tailored to specific groups such as teachers, fellow students as well as general community 
members to reduce their stigmatizing behavior towards HIV positive children. Advocacy for 
the formulation of peer support groups in the community and in schools should be encouraged 
to take a lead in advocating for love, care and support for HIV infected children.  
Conclussion 
In conclusion, evidence from this study suggests that, children not living with both parents, 
are more likely to have worse adherence to ART, in part due to an inadequate support 
environment in school and within the nuclear or extended family. 
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Figure 2: Flow diagram of the study participants 
 
 
* On Travel meant the patients was not within Ifakara town. Subjects had traveled outside 
Ifakara for various reasons 
**These are patients who transferred out without having transfer permit from the clinic 
 
 
 
  
Refused 
 n=2 (5%) 
(5%) 
Missing adherence 
information 
(Excluded from the 
analysis) n=7 (6%) 
 
Not available 
n=28 (70%) 
 
Patients approached 163 
 
Died,  
n = 10 (25%) 
Included in the study 
analysis n=116 
(94%) 
 
Interviewed patients, n =123 (75%) Not interviewed, n =40 (25%) 
Transfer** 
n=12 (43%) 
      
On Travel* 
n=2(3%) 
Wrong address 
n=15     (54%) 
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Table 3: Summary of characteristics of patients by response status 
 
 
  
 
Responders  Non-Responders  P-Value 
  Variable n % n  %   
  Sex 
 
  
 
    
     Male 67 58 24 51   
     Female 49 42 23 49 0.40 
  Age categories (yrs) 
 
  
 
    
     2-5 30 26 16 34   
     6-11 46 40 15 32   
     12+ 40 34 16 34 0.51 
  WHO stage 
 
  
 
    
     Stage I & II 31 27 14 30   
     Stage III & IV 40 34 27 57   
     Missing 45 39 6 13 0.59 
  Distance to clinic 
 
  
 
    
     <5km 93 80 43 91   
     >5km 23 20 4 9 0.08 
  
Duration on ART 
(yrs) 
 
  
 
  
  
     0-2 46 40 11 23   
     >3 60 52 20 43   
     Missing 10 9 16 34 0.43 
 
WHO stage= World Health Organization clinical stage; yrs=years; 
km=Kilometres; %= Column percentages 
  
65 
 
Table 4: Summary of characteristics of participants by adherence categories 
  
  
 
Optimal Suboptimal P-Value 
    Variables n % n %   
    Sex 
    
  
    Male                                                                                               46 69 21 31   
    Female                                                                                                           35 71 14 29 0.75 
    Age-school  
    
  
    Pre-school age 2-5yrs                            23 77 7 23   
    >6yrs never been to school 11 58 8 42   
    Primary school age and in primary 21 70 9 30   
    Secondary school but in primary 19 70 8 30   
    Secondary school age and in secondary 7 70 3 30 0.74 
    Baseline CD4 + cell count 
    
  
    Below 350 cells/mm3 33 66 17 34   
    Above 350cells/mm3      42 71 17 29   
    Missing                                6 86 1 14 0.54 
    Age specific immunosuppression 
    
  
    Not Immunosuppressed 61 70 26 30   
    Immunosuppressed 16 67 8 33   
    Missing 4 80 1 20 0.83 
    Duration under ART 
    
  
    0-2 yrs  30 65 16 35   
    >2 yrs 41 68 19 32   
    Missing  10 100 0 0 0.09 
    Parental status 
    
  
    Both parent  32 82 7 18   
    Single parent 20 67 10 33   
    Non-parental caretaker           29 62 18 38 0.11 
    Knows that treatment is lifelong 
    
  
    Yes 57 70 24 30   
    No  24 69 11 31 0.85 
    Disclosure of HIV status 
    
  
    Yes 25 64 14 36   
    No 53 75 18 25   
    Missing 3 50 3 50 0.29 
    Adherence assistance 
    
  
    Parents 48 74 17 26   
    Non-parental adherence assistants  33 65 18 35 0.29 
    Visited traditional healer for HIV cure* 
    
  
    Yes 15 75 5 25   
    No 66 69 29 31   
    Missing 0 0 1 100 0.28 
    Pill Burden 
    
  
    1 pill 35 69 16 31   
    2-3 pills 46 71 19 29 0.80 
    Joined any HIV support group   
   
  
    Yes 12 57 9 43   
    No 69 73 26 27 0.16 
    WHO clinical staging 
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     Stage I & II 20 65 11 35   
     Stage III & IV 26 65 14 35   
     Missing 35 78 10 22 0.33 
    Socioeconomic status 
    
  
    Low 30 73 11 27   
    Median 16 73 6 27   
    High 27 63 16 37   
    Missing 8 80 2 20 0.61 
  
Poor adherence=less than 80%;optimal adherence=80% or more; WHO= World Health 
Organization;yrs=years; * visited a healer who claimed to have a cure for HIV/AIDS; Immune-
suppressed if CD4 <500 cells/mm
3
 for children aged <6 years and if CD4<350 cells/mm
3
 for children 
aged 6 years and above;%=Row percentages; p=Chi2 P-value 
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Table 5 Univariate logistic regression of predictors of poor adherence among children 
    Univariate analysis   
  Variable OR 95% CI P-Value 
 
  Sex 
  
  
 
  Female 0.88 0.39-1.96 0.748 
 
  Age-School 
  
  
 
  Pre-school age 2-5yrs                      1 
 
  
 
  >6yrs never been to school 2.39 0.69-8.28 0.170 
 
  Primary school age and in primary 1.41 0.45-4.45 0.560 
 
  Secondary school age but in primary 1.38 0.42-4.5 0.591 
 
  Secondary school age and in secondary 1.41 0.29-6.9 0.674 
 
  Baseline CD4 + cell count 
  
  
    Below 350/mm3 1 
 
  
  
  Above 350/mm3      
0.79 0.35-1.77 0.561 
 
  Age specific immunosuppression 
  
  
 
  Not Immunosuppressed 1 
 
  
 
  Immunosuppressed 1.17 0.46-3.08 0.746 
 
  Duration under ART 
  
  
 
  0-2 years 1 
 
  
 
  >2 years 0.88 0.38-1.96 0.735 
 
  WHO stage 
  
  
     Stage I & II 1 
 
  
     Stage III & IV 0.98 0.37-2.61 0.966 
 
  Visited Traditional Healer for HIV cure* 
  
  
 
  No 1 
 
  
 
  Yes 0.76 0.25-2.28 0.623 
 
  Pill burden 
  
  
 
  1 pill 1 
 
  
 
  2-3 pills 0.90 0.41-2.0 0.803 
 
  Disclosure of HIV status 
  
  
 
  Yes 1 
 
  
 
  No 0.61 0.26-1.41 0.246 
 
  Joined any HIV support group 
  
  
 
  Yes 2.0 0.75-5.27 0.166 
 
  Adherence Assistance 
  
  
 
  Parents 1 
 
  
 
  Non-parental adherence assistants  1.54 0.69-3.41 0.288 
 
  Knows that treatment is lifelong 
  
  
 
  No 1 
 
  
 
  Yes 1.65 0.71-3.84 0.246 
 
  Socio-economic status 
  
  
 
  Low 1 
 
  
 
  Median 1.02 0.32-3.3 0.970 
 
  High 1.62 0.64-4.08 0.310 
 
  Parental status 
  
  
 
  Both Parents 1 
 
  
 
  Single parent 2.29 0.75-6.98 0.200 
 
  Non-parental caretaker           2.84 1.04-7.77 0.042 
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*Visited a healer who claimed to have a cure for HIV/AIDS; Poor adherence=less than 80%;optimal 
adherence=80% or more; Immune-suppressed if CD4 <500 for children aged <6 years and if CD4<350 for 
children aged 6 years and above; WHO=World Health Organization; yrs=years; CI =confidence interval; OR=odds 
ratio. 
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CHAPTER FIVE: Adherence among patients attending a rural 
HIV clinic in Tanzania 
ABSTRACT 
Introduction 
Adherence to antiretroviral therapy (ART) is one of the most important and one of the only 
modifiable risk factors that affect treatment success. Our objectives were to describe ART 
adherence and to find determinants of non-adherence among patients enrolled in the 
Kilombero-Ulanga Antiretroviral Cohort in rural Tanzania. 
Methods 
A longitudinal study design including all patients on ART attending the clinic between June 
2011 and May 2012 was used. We collected information about adherence during the previous 
month. Non-adherence was defined as missing any ART dose in the month prior to the 
interview. To identify determinants of non-adherence over time, we constructed repeated 
measures logistic regression models. 
Results 
We interviewed 2146 patients during 9295 clinical visits over 12 months of follow-up. 
Overall the non-adherence level was ranging between 3.5 to 9.9%. Determinants of non-
adherence were the shorter duration on ART, having a low socio-economic status and living 
closer to the clinic.  
Conclusion 
Adherence levels  reported over time appear satisfactory in this rural, rather dispersed HIV-
treatment cohort during the study period. Additional efforts to improve adherence should 
target patients in the first weeks or months of ART initiation and with a particular focus on 
patients with low socio-economic status.  
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BACKGROUND 
 
There were 35.3 million people living with human immunodeficiency virus (HIV) in 2012 
(WHO, 2013b). Furthermore, 2.3 million new infections and 1.6 million deaths due to HIV 
occurred in 2012 (UNAIDS, 2013b). Sub-Saharan Africa is one of the regions most affected 
by morbidity and mortality from infection with HIV and has approximately two thirds of the 
world’s HIV infected persons (UNAIDS/WHO, 2008). In Tanzania, the estimated adult HIV 
prevalence was 5.1% by 2012, after a decrease from 5.7 in 2004 (TACAIDS, 2009b). Starting 
with the introduction of potent antiretroviral therapy (ART) in 1996, HIV changed from being 
a death sentence to a more manageable chronic illness. Increased political commitment and 
smarter investments, together with more strategic programming and massive reductions in the 
cost of treatment have led to a record 9.7 million people in low- and middle-income countries 
having access to antiretroviral therapy by the end of 2012 (UNAIDS, 2013b). The Tanzania 
HIV Care and Treatment Plan was launched in October 2004, aiming at providing 440,000 
AIDS patients with ART and tracking disease progression in 1.2 million HIV positive 
subjects by the end of 2009 (G. Somi et al., 2009). According to the World Health 
Organization (WHO) report on HIV treatment in 2013, only 40% of Tanzanian children and 
adults in need were receiving ART (WHO, 2013a). The main constrains for access to ART in 
Africa have been lack of infrastructure to procure and distribute drugs, inadequate numbers of 
trained health care staff, and the lack of adequate laboratory facilities to monitor patients 
receiving ART (Nkengason J. N, 2004).  
According to recent studies, ART regimens require 70–90% adherence in order to be effective 
(Nachega, Mills et al., 2010). The goal of modern ART is long-term HIV RNA suppression, 
enabling immune reconstitution, reducing HIV drug resistance and preventing clinical disease 
progression (Bangsberg, Moss, et al., 2004; Bangsberg, Porco, et al., 2004; Hammer et al., 
2006; Lima et al., 2009; Lima et al., 2008). Although ART is effective in reviving patients’ 
health and improving quality of life, there are several challenges associated with the 
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treatment. Irregular and incomplete drug dosing is common despite the efforts of providers, 
pharmaceutical manufacturers, and health systems to encourage adherence. Non-adherence to 
antiretroviral therapy in adult populations has been shown to range from 33%–88%, 
depending on how adherence is defined and evaluated (Friedland G, 1999). Adherence has 
been found to be the most important modifiable factor that affects treatment outcome because 
failure to adhere to prescribed HIV therapy may result in treatment failure (Glass et al., 2008; 
Nieuwkerk et al., 2001; Paterson, Swindells et al., 2000), development of drug-resistant 
strains (Bangsberg, Charlebois et al., 2003; Harrigan, Hogg et al., 2005; Parienti, Massari et 
al., 2004; Sethi AK, Celentano DD et al., 2003; von Wyl et al., 2013), worsening of the 
disease (Honghu Liu, 2001), death (Wood E, 2003) and increasing health care costs 
(McDonnell PJ et al., 2002). 
Because maintaining optimal adherence to sustain viral suppression over a lifetime remains a 
major challenge, there was a need to study adherence over time so as to design appropriate 
measures to improve ART uptake. We investigated factors that predict non-adherence among 
patients enrolled in an ART cohort in rural Tanzania.  
METHODOLOGY 
Settings 
The study was conducted in Ifakara town in the Kilombero district of the Morogoro region in 
the observational open HIV cohort (KIULARCO), at the CDCI in St Francis Referral Hospital 
(SFRH) (Mossdorf, Stoeckle et al., 2011; Mossdorf, Stoeckle et al., 2010; Stoeckle, 
McHomvu et al., 2006). 
Study design and plan 
The study was longitudinal in design and targeted all registered patients on ART attending the 
CDCI between June 2011 and May 2012. Eligible patients were interviewed during routine 
clinical visits. During each visit, detailed information on ART adherence was collected in 
addition to the routine data collection. The study staff was trained in interview techniques to 
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minimize recall and social desirability bias. The study baseline was defined as the date of 
registration at the CDCI. Patients were followed until they were loss to follow-up (defined as 
those who joined the study but were not seen the last three months before the study ended) or 
the study ended.   
Treatment initiation at CDCI 
During the study period, all patients with CD4 count <350 cells/µl of whole blood, patients 
with WHO stage IV regardless of CD4 count, and pregnant women with WHO stage III or IV 
regardless of CD4 count were eligible to start ART (WHO, 2010b). Additionally, patients 
were required to come to the clinic with an adherence assistant who was to help the patients 
take their ART correctly. After treatment initiation, patients are required to visit the clinic on 
monthly basis for drug refill. 
Outcome 
The outcome of the study was adherence as measured by self-report. The adherence 
questionnaire was filled out during an interview by study staff. The adherence questionnaire 
recorded missed doses in the past three days and the past month prior to the interview, reasons 
for skipping medications, and if the patient ever changed or substituted the regimen 
(Appendix 1). A question regarding treatment interruption (if the patient ever stopped the 
drug in the previous 12 months) was added to the original questionnaire in December 2011. 
Non-adherence was defined as missing any ART dose in the past month prior to the interview. 
Optimal adherence was defined as not missing any ART dose in the month prior to the 
interview.  
Predictor variables 
The following variables recorded during ART initiation (at baseline) and during clinical visits 
(follow-up) were considered as predictors in our study:  
The baseline variables were gender, marital status, age, travel distance to the clinic, 
socioeconomic status (SES), smoking, alcohol consumption (defined has said to drink 
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alcohol), functional status, WHO clinical staging. The follow-up variables were years 
attending CDCI, change in ART, type of non-nucleoside reverse transcriptase inhibitor 
(NNRTI), time on ART (measured by the number of visits), functional status, history of 
chronic illness (tuberculosis infection, hypertension, cancer and diabetes) , time on study 
(measured by frequency of interviews) and WHO clinical staging. 
Collection of socioeconomic data 
We collected data on socioeconomic status (SES) once using an asset survey from June 2011 
to September 2011 among 1935 patients under ART in KIULARCO (Appendix 2). SES was 
assessed by constructing a household ‘wealth index’ based on scores calculated from asset 
ownership and building materials. This approach used principal component analysis (PCA), 
which transforms a number of correlated variables into a smaller number of uncorrelated 
variables (Filmer et al., 2001; Vyas et al., 2006). PCA allows variables that are collinear to be 
grouped together to form a composite index capable of representing the group of variables 
itself. Ownership of the following assets was considered: electricity, lamp, radio, television, 
mobile phone, land line, iron, refrigerator, wrist watch, bicycle, motor bike, motorcar, and 
having a bank account. Building materials considered were mud, bamboo, wood, tiles, 
cement, carpet, grass, post, sun-dried bricks, fired bricks, cement bricks, wood, iron sheets, 
tiles, concrete and fabricated bricks. The first component of the PCA was considered to 
represent SES and the score was divided into tertiles as low, middle, and high SES (Nikoi & 
Odimegwu, 2013). 
Data processing and analysis 
Data were double-entered and verified using EPI-DATA (EpiData Association, Odense, 
Denmark) and analysed using STATA 12.0 (STATA Corp., College Station, Texas, USA).  
Baseline characteristics were summarized using mean, median and percentages. To identify 
determinants of adherence over time, we constructed repeated measures logistic regression 
models. Generalized estimating equations were utilized to account for the clustering due to 
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the repeated responses in the same individuals. Results were presented with odds ratios (OR) 
and 95% confidence intervals (CI). 
Ethical statement 
The study was undertaken as part of the KIULARCO (Mossdorf Erik et al., 2011) operational 
research that received ethical and research clearance from the Ifakara Health Institute 
Institutional Review Board, the National Research Ethics Committee, Medical Research 
Coordination Committee of the National Institute for Medical Research (NIMR) through  the 
Tanzania Commission for Science and Technology (COSTECH). Patients provide written 
consent upon entering the cohort. We also obtained oral consent from each participant 
interviewed in the study. 
RESULTS 
Data Flow 
Of the 2146 participants on ART registered in KIULARCO and attending the CDCI during 
the study period, all agreed to participate in the study. Over the 12 month study period, we 
conducted 9295 interviews. Patients were interviewed during scheduled and unscheduled 
CDCI visits with a median number of 3 (IQR: 2-4) visits. A total of 556 (25.9%) were lost to 
follow-up before the study ended. 
Baseline characteristics 
The study was composed of 67% females, 43% aged between 20-40 years, 34% had high 
SES, 14% had an history of comorbidities, 46% were married or cohabiting, 59% were 
residing 5 km or less from the CDCI, 69% were in WHO clinical stage I and II, 28% reported 
to drink alcohol, 13% reported to smoke cigarette, 88% had nevirapine-based ART as their 
initial regimen and 17.8% had history of comorbidities as summarised in Table 6.   
Non-adherence and treatment interruptions 
Among the visits with a non-missing outcome observation, 3.5% (326/9281) reportedly 
missed an ART dose in the previous 3 days, 9.1% (837/9237) did not miss a dose in the 
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previous 3 days but missed a dose in the past month and 9.9% (922/9281) missed at least one 
dose in the month prior to the interview. At least 12.5% of participants reported to have 
missed a dose in the past 3 days and in the past month prior to the interview. Non-adherence 
reporting was less frequent in November 2011 and in the fourth visit. Non-adherence 
reporting was more frequent in September 2011 and in the eighth visit as shown in figure 1. 
The main reasons for missing doses were forgetfulness (48%), running out of pills (19%) and 
being away from home (17%) as shown in in table 2. During the study period, 8.8% 
(188/2146) of the participants reported to have interrupted ART during the previous year 
(Table 8). The median duration of ART interruptions was 15.5 days (IQR: 7-90).  
Univariate and multivariate regression 
In the univariate analysis, risk factors for non-adherence during the 12 month study were low 
SES, shorter duration on ART, younger age, time on study and poor clinical status (lower 
functional status). After adjusting for all prior selected variables of interest lower SES, shorter 
duration on ART, travel distance to the clinic and time in the study predicted non-adherence. 
For each additional year on ART at baseline (ART initiation), an individual was 11% less 
likely to report non-adherence (OR: 0.89, 95% CI: 0.81-0.96). Although not statistically 
significant, study participants with low SES were more likely to report non-adherence (OR: 
1.29, 95% CI: 0.95-1.74) compared to patients with high SES. Patients residing more than 5 
km from the clinic were less likely to report non-adherence levels (OR: 0.79, 95% CI: 0.61-
1.03) compared to patients residing within 5 km from the clinic (Table 9). The relationship 
between number of interviews and adherence reporting was U-shaped showing optimal 
adherence reporting was highest at the initial interview(s) then declined during the subsequent 
visits before improving in the last visits of the study. Residing near the CDCI and smoking 
were the risk factors for treatment interruptions (Table 9).  
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DISCUSSION  
This longitudinal study found that patients on ART for longer periods, time participating in 
the study and travel distance (to the CDCI) were associated with adherence to ART.   
The study had a large sample size (>2000) and followed patients over a long period (up to12 
months) in a programmatic setting (no intervention, no additional visits). The study may have 
been subject to recall and social desirability bias but we trained staff in interview techniques 
to try to minimize these potential biases. The drugs used during the study were not recorded 
as fixed combinations but as separate drugs, which made assessing the effect of pill burden on 
adherence practically impossible. Patients reported good adherence during the 12 months of 
the study with only 12.5% of participants reported to have missed a dose during follow-up 
and 8.8% had experienced treatment interruptions. This is in line with studies done in Africa 
settings that report high adherence (Amberbir, Woldemichael et al., 2008; Bangsberg et al., 
2001; Coetzee, Boulle et al., 2004; Oyugi, Byakika-Tusiime et al., 2004; S. Weiser et al., 
2003). Despite challenges with access to ART, patients in developing countries and 
particularly also in peripheral health systems settings  achieve remarkable adherence levels 
similar to or higher than those of patients in developed countries (Orrell et al., 2003). The 
adherence levels achieved reflect the success of the strategy to engage with individual 
adherence assistants as a prerequisite to initiate ART as established for this large ART-cohort 
since its inception in 2005 (Mossdorf, Stoeckle et al., 2011; Mossdorf, Stoeckle et al., 2010; 
Stoeckle, McHomvu et al., 2006). Non-adherence to ART followed the agricultural cycles and 
reflect how people set their individual priorities when basic needs need to be met. This 
interesting finding will be explored further to improve all Information Education and 
Communication (IEC) efforts as well as training of health staff and treatment assistants. The 
main reasons reported for missing doses of ART among our participants were forgetfulness 
and running out of pills, which is very similar to studies done in other rural and urban settings 
of Africa (Habib et al., 2010; Tiyou et al., 2010) and the United States (Amico et al., 2007) 
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but different from a study done in Europe (Italy) which found that confusion and poor 
psychological well-being were reasons for missed doses (Murri et al., 2000).  
Our study has shown that more experienced patients reported better adherence compared to 
less experienced individuals. This is similar to studies done in Nepal (Wasti et al., 2012) and 
in the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) Studies 
to Evaluate Resistance Monitoring (TASER-M) (Jiamsakul, Kumarasamy, et al., 2014). A 
study done in the United Kingdom also revealed that adherence did improve over a median of 
4.5 years (Cambiano et al., 2010). This might be due patient’s delay to incorporate HIV 
infection and treatment status into self-identity.  Initial reactions to HIV diagnosis include 
shock, fear, denial, or relief followed by post-diagnosis turning point which is often initiated 
by a person need to access ART (Baumgartner, 2007; Baumgartner et al., 2009). Some HIV 
patients believe HIV medication is necessary only when one is sick (Fagan et al., 2012)  and 
this is evident because most HIV positive clients present to the clinic when the disease is at an 
advanced stage (Antinori et al., 2011). Since our study was longitudinal and attrition increases 
over time, a larger proportion of longer term ART users has dropped out of KIULARCO prior 
top start of this study than for short term users. Since the drop-outs are also more likely to 
have been non-adherers (because non-adherence increases risk for mortality and Lost to 
follow-up (LTFU), the group of long term ART users is a biased selection of the better 
adhering patients. 
The study has shown that patients residing far from the clinic are less likely to report non-
adherence. This is most interesting since it is generally expected that people from far should 
report lower adherence since the areas may not be well-resourced (Harvey et al., 2008). 
Studies have shown that in rural settings, optimal adherence tends to increase over time 
(Birbeck et al., 2009). Since rural populations live in a more communal setting, the positive 
impact of ART on HIV positive-patients might be more visible, which may positively 
influence optimal adherence. The association between distance and non- adherence might also 
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be explained by the fact that patients coming from outside Ifakara town incur more time and 
cost and hence have a sense of utilizing the opportunity to the fullest. They might be afraid 
that failure to adhere to drugs might increase their chances of developing other comorbidities 
which will add be more cost burden on to them. We are currently investigating these 
possibilities further.  
Study participants with low SES were more likely to report lower adherence levels compared 
to those with high SES. This association might be linked by the fact that patients with low 
SES have inability to get enough and/or quality food as seen in previous studies (Berhe et al., 
2013). Individuals on ART who lack resources are prone to malnutrition due to inadequate 
dietary intake, appetite loss, nutritional losses, metabolic changes, and increased requirements 
for both macro and micro-nutrients (Ivers et al., 2009). A study done previously in Botswana, 
Uganda and Tanzania found that a quarter of patients on ART fail optimal adherence due to 
nutritional, social and economic conditions (Hardon, Akurut et al., 2007). Patients with low 
SES are more likely to have excessive sedentary lifestyle, unhealthy dietary habits and 
excessive alcohol consumption. Because of the pronounced prevalence of unhealthy lifestyle 
among the poorest, they have often been blamed for having inappropriate health behaviors 
that may prevent them from seeking the care that they need (Jones et al., 1998). In other study 
settings, parameters of SES have been associated with non-adherence. Lower education is 
consistently associated with lower HIV medication adherence across geographic and 
economic settings (Fogarty et al., 2002; Rachlis et al., 2011). 
In conclusion, we have systematically identified low SES, ART naïve and Proximity as 
predictors of non-adherence. Furthermore the study has shown good adherence reporting 
during agricultural periods. Additional efforts through targetted IEC should focus on (i) 
patients at the start of ART, i.e.  in the first weeks,  and (ii) the poor patient segments.   
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         Table 6: Patients baseline characteristics 
  Variables          N (%) 
  Sex    
    Female 1436 (67) 
    Males 695 (33) 
  Age (years)   
    0-20 215 (10) 
    21-40 923 (43) 
    >40 994 (46) 
  Age (years)   
    Mean (SD) 38.2(13.6) 
    Median (IQR) 39.1 (32-46.6) 
  Marital Status   
    Married/Cohabitating 945 (46) 
    Single/Never married 609 (29) 
    Divorced/Separated/Widowed 515 (25) 
  Distance from home to CDCI   
     <=5km 1021 (59) 
 
   >5km 878 (41) 
 
WHO clinical stage   
 
    Stage I & II 1468 (69) 
 
    Stage III & IV 649 (31) 
 
Smoking   
 
   Yes 264 (13) 
 
   No 1732 (87) 
 
Alcohol consumption   
 
   Yes 555 (28) 
 
   No 1442 (72) 
  Functional status   
    Working 1904 (92) 
    Ambulatory/Bedridden 155(8) 
 
Duration attending CDCI (months)   
 
  Mean (SD) 5.5 (10.5) 
 
  Median (IQR) 0.87 (0.17-5.2) 
 
Duration living with HIV (Months)   
 
  Mean (SD) 7(13.4) 
 
  Median (IQR) 2.3 (0.53-9.4) 
 
First ART regimen   
 
  Nevirapine based 1134 (87) 
    Efavirenz based 168 (13) 
  History of chronic co-morbidities*   
    Yes 292 (14) 
 
  No 1854 (86) 
 
Socioeconomic status   
 
  Low 594 (34) 
 
  Middle 544 (32) 
 
  High 588 (34) 
  
  *Comorbidities included hypertension, diabetes, TB, and cancer. SD=standard deviation, 
IQR=interquartile range 
      
80 
 
 
Table 7: Treatment Adherence, interruptions levels and reasons for missed doses 
  
 
Adherence outcome 
Percentage (All  
visits) 
Percentage 
(patients) 
 
   Missed dose in the past 3 days 3.5 (326/9281) 4.5 (93/2056) 
 
     Not Missed 94.3 (8749/9281)   
 
     One day 2.2 (202/9281   
 
     Two days 0.87 (81/9281)   
 
     Three days 0.46 (43/9281)   
 
     Not known 2.2(206/9281)   
 
  Missed dose in the previous month 9.1 (837/9237) 9.0 (190/2121) 
 
     Not missed 93.1(8597/9237)   
 
     Last week 1.26 (116/9237)   
 
     1-2 weeks 1.29(119/9237)   
 
     2-4 weeks 3.8 (348/9237)   
      Not known 0.8 (7/9237)   
    Combined missed dose 9.9 (922/9231) 12.5 (265/2123) 
    Treatment interruption (days)* (15.5:7-90) 8.8 (189/2146) 
    Reasons for missed dose     
 
   Forget   48(199/411) 
 
   Ran out of pills   19(77/411) 
 
   Away from home   17 (68/411) 
 
   Too ill   7(30/411) 
 
   Others   9(37/411) 
 
*The denominator of treatment interruption was no of participants because the question was about adherence in the 
previous year, (Med:IQR) 
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        Table 8 Univariate and multivariate logistic regression models of non-adherence 
 
 
 
  
    Univariate   Multivariate   
  Variable OR 95% CI P-value OR CI P-value 
  Sex 
  
    
 
  
  Female 0.96 0.80-1.14 0.615 1.03 0.79-1.35 0.809 
  Marital status             
  Married/Cohabitating Ref 
 
  Ref 
 
  
  Never married 1.10 0.86-1.29 0.622 1.02 0.75-1.40 0.900 
  Separated/Widowed 1.00 0.79-1.23 0.881 1.01 0.73-1.39 0.972 
  Socio-economic status             
  High Ref 
 
  Ref 
 
  
  Middle 1.21 0.95-1.53 0.117 1.23 0.91-1.67 0.172 
  Low 1.23 0.97-1.55 0.089 1.29 0.95-1.74 0.095 
  Age in years (per 10 years) 0.93 0.88-0.99 0.020 0.96 0.88-1.06 0.441 
  Season             
  Dry* 1.10 0.93-1.23 0.309 1.05 0.80-1.37 0.724 
  Duration under ART (year)  0.92 0.87-0.96 <0.001 0.86 0.81-0.96 0.007 
  Nevirapine/Efavirence             
  Efavirenz based 0.82 0.63-1.05 0.115 0.79 0.59-1.06 0.111 
  WHO clinical staging             
  Stage III and IV 0.99 0.84-1.17 0.914 1.07 0.85-1.38 0.566 
  Ever changed ART   
 
    
 
  
  Yes 1.21 0.96-1.51 0.102 0.98 0.66-1.43 0.908 
  Travel distance to the CDCI             
  More than 5 km 0.95 0.80-1.14 0.529 0.79 0.61-1.02 0.082 
  Alcohol drinking   
 
  
  
  
  Yes 0.99 0.81-1.20 0.888 1.18 0.88-1.57 0.267 
  Smoking             
  Yes 0.94 0.73-1.22 0.657 0.72 0.48-1.09 0.122 
  Functional status             
  Ambulatory/Bedridden 2.05 0.88-4.79 0.060 1.46 0.27-7.73 0.660 
  History of comorbidities** 
  
  
  
  
  Yes 1.00 0.76-1.30 0.977 0.75 0.47-1.18 0.215 
  Time on study+             
  No of interviews 0.93 0.89-0.97 0.002 0.82 0.70-0.97 0.024 
  
*Dry months are from May to December, **comorbidities include Hypertension, TB, Cancer or diabetes, 
Ref: Reference, + square term included 
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Table 9:  Univariate and multivariate logistic regression models of baseline predictors 
 
 
 
 
    
    Univariate     Multivariate   
  Variable OR 95% CI P-value OR CI P-value 
  Sex 
  
    
 
  
  Female 0.92 0.67-1.27 0.615 1.19 0.74-1.90 0.469 
  Marital status             
  Married/Cohabitating Ref 
 
  Ref 
 
  
  Never married 1.04 0.73-1.47 0.834 0.91 0.54-1.53 0.712 
  separated/Widowed 0.85 0.58-1.26 0.422 0.71 0.41-1.23 0.221 
  Socio-economic status             
  High Ref 
 
  Ref 
 
  
  Middle 0.91 0.57-1.44 0.680 0.84 0.41-1.23 0.500 
  Low 0.86 0.56-1.39 0.597 0.9 0.51-1.39 0.681 
  Age in years (10 years) 0.88 0.79-0.98 0.020 0.91 0.76-1.09 0.312 
  Travel distance to the CDCI             
  More than 5 km 0.9 0.66-1.23 0.515 0.67 0.43-1.06 0.078 
  Alcohol drinking   
 
  
  
  
  Yes 1.05 0.74-1.49 0.773 0.78 0.48-1.27 0.316 
  Smoking             
  Yes 0.96 0.61-1.50 0.842 2.36 1.03-5.43 0.043 
  Functional status*             
  Ambulatory/Bedridden 1.14 0.65-1.98 0.651 0.87 0.38-1.94 0.573 
  History of comorbidities** 
  
  
  
  
  Yes 1.27 0.85-1.91 0.241 1.22 0.61-2.42 0.574 
 
 **comorbidities include Hypertension, TB, Cancer or diabetes, Ref: Reference,  
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Figure 3:Non-adherence by order and month of visits 
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APPENDIX 1 : ADHERENCE QUESTIONNAIRE  
                                                 
ST. FRANCIS 
DESIGNATED DISTRICT HOSPITAL 
IMANI 
NA 
AFYA 
                                                                                                                                                      
1. Patient Name           ________________________________________________ 
2. NACP NO               ______________________________ 
3. Date of visit              ____/_____/_____ 
4. Did you ever miss ARV dose  in the past 3 days        
(a) No    
(b) One day 
(c) Two days  
(d) Three days    
(e) Not known  
5. Prior to the 3 days when did you last miss medication? 
(a) Last week   
(b) 1 – 2 weeks    
(c)  2 – 4 week    
(d) Never skipped a medication    
(e) Not known 
6. Have you ever stopped medication in the past year (q)? 
(a) Yes    if yes for how long?  _________________________ 
(b) No     
    7.   Reason for missing ARV medication             
(a) Toxicity 
(b) I just forgot 
(c) Share with others  
(d) Stock out 
(e) Felt better  
(f) Too ill 
(g) Ran out of pills 
(h) Stigma 
(i)  Alcohol 
(j) Influenced by someone else  not to take the drug 
(k) I felt depressed 
(l) Too many pills 
(m)  I was away from home 
(n) I was busy with other things 
(o) Refused to answer  
(p) don’t know  
(q) Other:   Mention ……………………………………… 
 
  8. Which facility did you last visit to take your medication? 
  ________________________________________________ 
  9. (i) Have you ever Change/substitute ARV  since you started? 
(a) Yes (if yes then go to Qn. 10 
(b) No 
10. Date of ARV change 
(a)  Change 1.       Date              ____\____\________  
(b) Change 2.       Date              ____\____\________ 
(c) Change 3.       Date              ____\____\________ 
  11. Reasons for change in drug 
(a) TB or adverse reactions.   
(b)  Treatment failure 
(c) Poor adherence 
(d) Pregnancy 
(e)  End of PMCT 
(f) Stock out 
(g) Patient decision                                    
(h)  Others   _______________________________ 
12. Interviewer code                                                        ___\ ____                
(q). 
this question was added on 15/12/2011 
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APPENDIX 2: SOCIO-ECONOMIC STATUS QUESTIONNAIRE 
1. Date of interview   
2. Nacp No   
3. Name of the patient  
What is the main source of drinking 
water for your family?  
 
□ 01. Piped Water into dwelling/yard/plot  
□ 02. Shared tap/stand pipe  
□ 03. Public tap / stand pipe  
□ 04. Tube well/borehole  
□ 05. Protected dug well  
□ 06. Protected spring  
□ 07. Rain water  
□ 08. Unprotected dug well  
□ 09. Unprotected spring  
□ 10. Tanker truck/cart with small tank  
□ 11. Surface water  
□ 88. Don’t know 
Who is your main water provider?  
 
□ 1. Authority  
□ 2. Community Based Organization/ Non Governmental Organization  
□ 3. No provider  
□ 8. Don’t know  
How long does it take you to go get 
water and come back?  
 
Mins: 
□ 2. On premise  
□ 8. Don’t know  
What kind of toilet facility do members 
of your household usually use?  
 
□ 1. Flush or pour flush toilet  
□ 2. Ventilated Improved Pit latrine (VIP)  
□ 4. Traditional pit latrine  
□ 5. No facility/bush/field  
□ 6. Other:  
Do you share this toilet facility with 
other households?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
Does your household have:  
 
Electricity?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A paraffin lamp?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A radio?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A television?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A mobile telephone?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A non-mobile telephone (landline)?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
An electric or charcoal iron?  
 
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A refrigerator?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
What type of fuel do you use the most 
in your household for cooking?  
 
□ 01. Electricity  
□ 02. Bottled gas  
□ 03. Paraffin/ Kerosene  
□ 04. Charcoal  
□ 05. Firewood  
86 
 
□ 06. Crop residuals, straw, grass  
□ 07. Animal dung  
□ 08. No food cooked in household  
□ 66. Other:  
 
What is the main source of lighting in 
the household?  
 
□ 01. Electricity  
□ 02. Solar  
□ 03. Gas  
□ 04. Paraffin hurricane lamp  
□ 05. Paraffin pressure lamp  
□ 06. Paraffin wick lamp  
□ 07. Firewood  
□ 08. Candles  
□ 09. Other:  
 
What is the main material on your 
floor?  
 
□ 01. Earth/Sand/Dung  
□ 02. Wood planks, bamboo, palm  
□ 03. Parquet or polished wood  
□ 04. Vinyl or asphalt strips  
□ 05. Ceramic tiles, terrazzo  
□ 06. Cement  
□ 07. Carpet  
□ 08. Other:  
□ 88. Don’t know  
 
What is your wall made of?  
 
□ 01. Grass  
□ 02. Poles and mud  
□ 03. Sun dried bricks  
□ 04. Baked bricks  
□ 05. Wood/ timber  
□ 06. Cement blocks  
□ 07. Stones  
□ 08. Other:  
□ 88. Don’t know  
 
What is your roof made of?  
 
□ 1. Grass/thatch/mud  
□ 2. Iron sheets  
□ 3. Tiles  
□ 4. Concrete  
□ 5. Asbestos  
□ 6. Other:  
□ 8. Don’t know  
How many rooms in your household 
are used for sleeping?  
No. of rooms:  
Does any member of your household own:  
A watch?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A bicycle?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A motorcycle?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A car or a truck?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
A bank account?  
 
□ 0. No  
□ 1. Yes  
□ 8. Don’t know  
 
Did you worry that your household 
would not have enough food?  
□ 0. No -> go to question 72  
□ 1. Yes-> go to question 71  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Was there any time when you or any of 
your household members could not eat 
the food you wanted because you 
□ 0. No -> go to question 74  
□ 1. Yes-> go to question 73  
□ 8. Don’t know  
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Source: Questions taken from ‘ICC Form 3’ 
 
 
 
 
 
 
 
 
  
didn’t have resources?  
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks) 
□ 8. Don’t know   
Was there ever a time when you or a 
household member had to eat a limited 
variety of foods due to a lack of 
resources?  
□ 0. No -> go to question 76  
□ 1. Yes-> go to question 75  
□ 8. Don’t know  
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Did you or a household member have 
to eat some foods that you didn’t want 
to eat because of lack of resources to 
obtain other foods?  
□ 0. No -> go to question 78  
□ 1. Yes-> go to question 77  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Did you or a household member ever 
compromise on the portion of food you 
ate because there was not enough?  
□ 0. No -> go to question 80  
□ 1. Yes -> go to question 79  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Was there any point where you or your 
household member had no food in the 
household because of lack of 
resources?  
□ 0. No -> go to question 82  
□ 1. Yes -> go to question 81  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Did you or a household member sleep 
hungry at night because of food 
shortages in the house?  
□ 0. No -> go to question 84  
□ 1. Yes -> go to question 83  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
Did you or a household member go 
hungry in day and night because of 
limited food in the house?  
□ 0. No  
□ 1. Yes -> go to question 85  
□ 8. Don’t know  
 
How often did this happen?  
 
□ 1. Rarely (1 – 2 times in the last 4 weeks)  
□ 2. Sometimes (3 – 10 times in the last 4 weeks)  
□ 3. Often (More than 10 times in the last 4 weeks)  
□ 8. Don’t know  
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CHAPTER SIX: ART resistance mutations in rural Tanzania: 
children and adolescents carry a heavy burden 
 
ABSTRACT 
Background 
Due to the limited access to second and third line therapy regimens in resource limited 
settings, the extended preservation of first line drugs is currently essential for better treatment 
outcomes among patients on ART This study aimed at estimating the level of treatment 
failure and viral resistance. In addition we set out to identify demographic and clinical factors 
associated with the occurrence of resistance related mutations during ART.  
Methods 
A cross-sectional study targeted 163 patients of all clinical staging and aged above two years 
who have been taking ART for at least six months. The study was done in a rural HIV clinic 
located in Tanzania. We assessed genotypic drug resistances by nucleotide sequencing and the 
Stanford HIV drug resistance database Version 6.2.0. Treatment failure to ART (defined as 
having a viral load of >100 copies/mL) and resistance mutations were expressed in 
proportions.  Univariate logistic regression was used to identify predictors of genotypic ART 
resistance.  
Results  
Out of 163 study participants, 12% were younger than 18 years. 62% received 
D4T+3TC+NEV as their first ART regimen, 69% were in WHO clinical staging I and II and 
mean time on ART was 3.7 years. The level of treatment failure was 5.5% (9/163).  Eight of 
these failures had at least one treatment-relevant mutation by genotypic analysis. The overall 
rate of genotypic resistance to ART was 4.9% (8/163). The proportion of treatment-relevant 
mutation was higher among younger participants 31.6% (6/19) than among adults 1.4% 
(2/144).  
Conclusion 
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The rate of genotypic resistance to ART was low (<5%) and the burden of resistance 
associated mutations was highest in participants under 18 years. This study underlines the 
importance of viral genotyping as a monitoring tool for HIV patients.  
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BACKGROUND 
An estimated 35.3 million [32.2–38.8 million] people were living with HIV at the end of 
2013. According to UNAIDS, 3.3 million children had HIV globally, 2.9 million in sub-
Saharan Africa (UNAIDS, 2013c). By reducing HIV viral load and restoring immune 
function, ART has led to substantial reductions in HIV-attributable morbidity and mortality 
and has greatly improved the quality of life for people living with HIV. The ART coverage in 
low and middle-income countries represented only 34% (32-37%) of the 28.6 million patients 
who were eligible in 2013 (UNAIDS, 2013a). The public health approach to scaling up ART 
in resource-limited settings involves the use of standardized treatment regimens (National 
Aids Control programme, 2005). The approach allows providing services out of specialized 
centres, standardizing ART regimen and using immunological and clinical definitions to 
monitor HIV patients. The public health approach is less sensitive to predict virologic failure, 
especially in children (Emmett et al., 2010) and thus patients experience increased durations 
of unsuppressed viremia compared to those monitored with viral load elsewhere (Barth et al., 
2011).  
ART resistance is a cause and a consequence of treatment failure among HIV patients on 
treatment (Clavel & Hance, 2004; Tang & Shafer, 2012). The absence of a virologic response 
after ART initiation may indicate transmitted treatment-related resistant mutations (Little et 
al., 2002). In resource-limited settings, first-line ART for HIV-positive patients consists of a 
triple combination of nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs 
and NNRTIs). In such settings, protease inhibitors (PIs) usually form the core component of 
second-line therapy (Elliott et al., 2008). 
Chronic disease clinic Ifakara (CDCI) is a care and treatment clinic located in Ifakara town in 
Kilombero district and has providing outpatient services to HIV positive patients since 2005. 
It aims to implement care and treatment for HIV/AIDS patients according to the Tanzanian 
national AIDS control programme (NACP, 2008b).   
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We estimated virological treatment failure and viral genotypic resistance to ART and 
investigated demographic and clinical factors associated with treatment-relevant mutations. 
METHODS  
Study design and enrollment 
A cross-sectional study was performed on patients aged > 2years who had been on ART for 
more than six months. We enrolled patients who on ART who attended the Chronic Disease 
Clinic Ifakara (CDCI) in June 2013 during a routine visit, have been on ART for more than 
six months and willing to participate in the study. Patients who were critically ill and those 
with no post-ART plasma sample available were excluded from the study. 
Treatment initiation at CDCI 
During the study period, all patients with CD4
+
 cell  count <350 cells/µL, patients with WHO 
stage IV regardless of CD4
+
 cell  count, and pregnant women with WHO stage III or IV 
regardless of CD4 count were eligible to start ART (WHO, 2010b). Additionally, patients 
were required to come to the clinic with an adherent assistant who will help the patients to 
take their ART correctly. After treatment initiation patients had to adhere to scheduled clinical 
and drug refill visits. 
Study settings  
The study was conducted within the ongoing observational HIV cohort, Kilombero and 
Ulanga Antiretroviral Cohort (KIULARCO), at the CDCI in St Francis Referral Hospital 
(SFRH). The CDCI has been providing ART in Ifakara since 2005 (Mossdorf, Stoeckle et al., 
2011; Mossdorf, Stoeckle et al., 2010; Stoeckle, McHomvu et al., 2006) in accordance with 
guidelines of the Tanzanian National AIDS Control Program (NACP) (National Aids Control 
programme, 2005). All patients signed a written consent. 
Study conduct and outcome 
Viral load was performed on all participants recruited in the study. Those patients with 
>100copies/mL of RNA in their plasma sample were regarded as treatment failure. 
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Individuals with treatment failure were eligible for a viral genotyping yielding a binary 
outcome (with or without treatment-related mutation). The outcome was defined as presence 
or absence of ART resistance-associated mutations. 
Laboratory methods 
Blood sampling /volume/ storage: 
Blood samples (10-20ml) were obtained from participants during scheduled laboratory 
monitoring or when a physician requested the samples for taking urgent clinical decisions. 
The samples were then stored at -80
o
C for clinical and research purposes. The blood was 
centrifuged to separate the cells and plasma 
Sequencing 
Plasma was isolated and frozen at -80
0
C until testing for viral load or drug resistance. Plasma 
HIV RNA was extracted using the Quigen kit (QIAamp
® 
Viral RNA Kit) and quantified using 
the StepOne Real Time PCR system (Applied biosystem). For samples with detectable Viral 
Load, HIVDR genotyping was performed using the ABI Genetic Analyser (3130 Genetic 
Analyser) using an in-house PCR protocol. (http://hivdb.stanford.edu). We included all drug 
resistance mutations that conferred low, intermediate or high-level resistance. The consensus 
sequences were assessed for drug resistance mutations by using the Stanford University HIV 
Drug Resistance Database HIVdb program Version 6.2.0. 
Viral load ascertainment 
Viral load was determined with a One Step Real-Time PCR System (Applied Biosystems) by 
using a modification of the manufacturer‘s instructions. cDNA was synthesized as shown 
above, but using random primers (0.1 lg/ll). The cDNA was then quantified by qRT-PCR. The 
qRT-PCR reaction contained 12.5 ll TaqMan Gene Expression Master Mix, 0.125 ll forward 
primer M2227F, 5’AGC CTC AAT AAA GCT TGC CTT G-3’ (10 lM), 0.125 ll reverse 
primer M2228R, 5’-CGG GCG CCA CTG CTA G-3’ (10 lM), 0.5 ll of probe HIV-
FAM/BHQ with FAM as a reporter dye located at the 5’ end and a black hole quencher at the 
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3’ end, 5’-TGC CCG TCT GTT GTG TGA CTC TGG TAA-3’ (10 lM), 5 µl cDNA, 
andRNase free water to a final 25 µl reaction volume. qRT-PCR thermocycling conditions 
were as follows: incubation (50°C, 2 min), initial denaturation (95°C, 10 min), and 44 cycles 
of denaturation (95°C, 30 sec and annealing and extension (60°C, 1 min). Quantification of 
cDNA was done relative to triplicate standard curves generated in each run from serial 
dilutions of a plasmid containing a viral DNA insert. Three ‘‘no template’’ controls were 
included for each run. 
CD4 
+
 T cells 
A single platform technique (SPT) was used to enumerate CD4
+
 T-helper cells using BD 
TruCount tubes (BD Biosciences, San Jose, CA). Of EDTA whole blood was stained using 5 
µl monoclonal antibody mixture BD TriTEST CD3- FITC/CD4-PE/CD8-PerCP (BD 
Biosciences) followed by 450µl BD lysis and fixative solution. Data acquisition and analysis 
by the MultiTEST software were performed using a three-color BD FACS Calibur (Becton 
Dickinson Immunocytometry Systems 2350). 
Data management and analysis 
Amino acids with mixed genotyping results (mutation plus wild type) were grouped with 
resistance associated mutations. The risk variables investigated were: sex, residence, CD4+ 
cell count (at the time of ART initiation), WHO clinical staging (at the time of ART 
initiation), age at ART initiation (binary: younger participants i.e. <18 years, older 
participants more than 18 years), duration under therapy (defined as difference between cART 
initiation and date of sample collection dates) and initial ART regimen. During analysis 
missing values were left to be missing. The level of treatment failure and ART mutations 
were analysed by descriptive techniques. Univariate Logistic regression was used to find 
determinants of ART genotypic resistance mutations. Only univariate analyses were 
performed owing to a low sample size. 
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Ethical considerations 
The study was undertaken as part of the KIULARCO operational research (Mossdorf Erik, 
Marcel Stoeckle et al., 2011) which had received ethical and research clearance from the 
Ifakara Health Institute Institutional Review Board, the National Research Ethics Committee, 
Medical Research Coordination Committee of the National Institute for Medical Research 
(NIMR) through  the Tanzania Commission for Science and Technology (COSTECH). All 
patients have given written consent before participating into the study. Patients with cART-
related mutations had their drugs switched or changed to avoid a failing regimen.  
RESULTS 
Data characteristics 
Among the 163 participants enrolled, 69.3% (113/163) were females, 12% (19/163) were <18 
years old, 54.6% (89/163) resided within Ifakara town. At the time of cART initiation, the 
median CD4
+
 cells count level was 256.5cells/µL, 68.9% (112/163) were asymptomatic 
(WHO clinical stage I or II) and 62.4% (105/163) had d4T+3TC+NVP as their initial first line 
regimen. The mean duration on ART was 3.7 (0.4-7.8) years (Table 10). 
Treatment failure and drug resistance strains to cART 
Treatment failure to ART defined as a viral load >100 copies/mL, was observed in 5.5% 
(9/163) of participants. The median viral load among patients with treatment failure was 
11343 copies/ml (IQR: 2010-22623). Of the nine patients with a detectable viral load, eight 
had at least one cART-related mutation. We found a total of 7 different NRTI, 11 NNRTI and 
3 PI resistance-associated mutations. Among the seven different NRTI mutations there was 
only one major mutation (M184V) appearing in five patients representing 3.1% of the 
participants. According to the Stanford algorithm, there were six minor NRTI mutations 
namely L210W, V75M, T215Y, Y115F, M41L and L74I. Among the 11 different NNRTIs, 
the two major mutations (K103N (4 cases) and Y181C (1 case)) were found in six patients 
representing 3.7% of the participants. The nine minor NNRTI mutations were A98G, V108I, 
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K238T, V106M, H221Y, E138G, V90I, V179D and F227L. No major PI mutations among 
our participants were detected, however three minor treatment-related drug resistances were 
detected (L10I, L33F and T74S) as listed in Table 11.                 
Factors associated with resistance associated mutations 
Among the eight participants who had at least one resistance-associated mutation, 62.5% (5/8) 
were females, 75% (6/8) were young participants, who had been on ART for an average 2.8 
years (range: 1.2-4.6) as shown in Table 11. Overall, the rate of ART resistance associated 
mutations among younger participants was 31.6% (6/19) compared to 2.1% (3/144) in adults. 
The mean age of participants with and without treatment-related mutations was 16.7 years 
(95% CI 6.21-27.3) and 35.6 (95% CI 33.5-37.8) respectively. The association between age 
and resistance associated mutation was statistically significant (p<0.001). In terms of the 
burden of mutations, younger participants carried 93% (14/15) of the detected NRTI 
mutations, 80% (16/20) of NNRTI mutations and 33.3% (1/3) of the PI mutations. The most 
prevalent NRTI resistance associated mutations (RAM) in participants <18 years of age were 
M184V (5/6) and Y115F (3/6). V75M and M41L were also detected in two patients under the 
age of 18 years. The most common NNRTI mutations in participants <18 years was K103N 
which confers resistance to efavirenz and nevirapine. K103N was identified in half (3/6) of 
the participants of whom all were under 18 years. Other common NNRTI mutations in this 
group were A98G (2/6), V108I (2/6), K238T (2/6) and Y188F (2/6). Only one minor PI 
mutation (L10I) was found among younger participants. Only one adult participant with an 
NRTI resistance mutation M184V was observed. Among adults with NNRTI mutations only 
one patient had K103N, V106IM, V179D and F227L and two patients had PI resistance 
mutations namely L33F and T74S.  
The treatment failure rate among patients on cART for <2 years was 6.1% (2/33) compared to 
5.3% (7/131) among patients with >2 years. Both patients who had been on cART for less 
than 2 years had M184V and K103N resistance associated mutations in common. The mean 
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duration of therapy with and without drug associated mutations was 2.8 and 3.8 years 
respectively. Two patients who had been on ART for > 3.7 years shared the following 
mutations: M184V, T215Y, M184V and K103N.  
DISCUSSION 
Our study found that the level of HIV drug resistance in CDCI patients under ART was 
around 5% and, most importantly, that a higher proportion of the burden is in children and 
teenagers. The higher rate of treatment-related resistance among younger participants might 
be explained by previous exposure to single dose nevirapine, suboptimal dosing and non-
adherence to ART. 
No sequencing information on pre-ART samples was available, which makes it difficult to 
know if the resistance mutations were transmitted or not. For these children with treatment-
related resistances, there was no mother-child pair and no prior information on pre-delivery 
ART exposure thus linking treatment-related mutations to previously ART exposure was 
impossible. 
A high prevalence of drug-associated mutations after treatment failure has been reported in 
previous studies. A study done on patients from the TREAT Asia Studies to Evaluate 
Resistance-Monitoring study (TASER-M), found 92% of patients who failed first line drugs 
harbor treatment-related mutations (Jiamsakul, Sungkanuparph, et al., 2014). If treatment-
related mutations are not detected during therapy, they will eventually accumulate and dilute 
the effectiveness of the drug in use.  
In comparison to an earlier study conducted in the same setting in 2007 (Masimba, Kituma et 
al., 2013), the rates of treatment-related resistances seems to have changed. The proportion of 
major NRTI mutations has increased from 1.7% to 3.1% while that of NNRTI has slightly 
increased from 3.3% to 3.6%. The proportion of PIs mutations has dropped sharply from 
5.8% in 2007 to 1.8% in 2013. The reasons for these changes might be partly contributed by 
the fact that the previous study enrolled only HIV clients above the age of 18 years. The 
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increase of NRTI mutations might be attributed by suboptimal drug levels contributed by non-
adherence to therapies and unplanned treatment interruptions. Previous studies in other 
countries have shown that younger HIV positive clients have higher rates of non-adherence 
compared to adults (Bygrave et al., 2012; Evans et al., 2013; Nachega et al., 2009).  
The sharp drop in PIs resistance mutation might be explained by the fact that the younger 
participants were not exposed to the protease drug. The PIs are well known by their potency 
and high genetic barrier to resistance (Wainberg & Friedland, 1998). The study has found 
several thymidine analogue mutations (TAMs) as expected in resource limited settings where 
TAMs analogues are prescribed as first line therapy (Jiamsakul, Sungkanuparph et al., 2014). 
TAMS originally selected by zidovudine and stavudine confer reduced susceptibility to all 
NRTIs (Jiamsakul, Sungkanuparph et al., 2014). Mutation M184V which was found in five 
patients, causes high-level resistance to lamivudine and emtricitabine and low-level resistance 
to didanosine and abacavir. Resistance to abacavir increases if M184V occurs together with 
other TAMS (V. A. Johnson et al., 2013; Praparattanapan, Kotarathitithum et al., 2012; Shafer 
et al., 2008) associating with multi-NRTI drug resistance (V. A. Johnson, Calvez et al., 2013). 
This could become serious problem in Tanzania since NRTIs are widely used as a backbone 
to both first and second line drugs. The absence of more complex mutational patterns, 
conferring broad cross-resistance to most NRTIs in these findings, suggesting a controllable 
situation as NRTI is a backbone to first and second ART regimens. Currently resistances to 
NNRTIs are of particular concern in resource limited settings because this drug class forms 
the basis of all first line treatment regimens as well as for prevention of mother to child 
transmission (Wainberg et al., 2011; WHO, 2010a). The slight increase in NNRTI mutations 
among our participants might be partly explained by the exposure single dose nevirapine to 
pregnant mothers (McConnell et al., 2007), low adherence among younger participants as 
noted in previous studies(Bygrave, Mtangirwa et al., 2012; Evans, Menezes et al., 2013; 
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Nachega, Hislop et al., 2009). NNRTIs have low genetic barrier and thus require excellent 
adherence to avoid resistances to occur.  
Single-dose NVP can favor the selection of HIV-1 resistant mutants in mothers and infants. 
ART was available to a limited number of individuals since 1996 in Tanzania as mono and 
dual therapies (Kasang, Kalluvya et al., 2011; G. R. Somi, Kibuka et al., 2008)  and single 
dose nevirapine was given to HIV pregnant women few weeks before delivery to prevent 
vertical transmission (NACP, 2008b) from 2004 to 2010. Similarly, treatment-related resistant 
virus emerged as experienced in countries which were the first to introduce mono and dual 
ART therapies resistance (Grant et al., 2002; Little, Holte et al., 2002; Wensing et al., 2005). 
Due to lack of data we could associate previous ART exposure and genotypic resistances. 
Non-adherence among younger participants may partly explain the burden of resistance 
associated mutations in younger participants. Earlier reports have shown poorer adherence in 
adolescents compared to adults (Bygrave, Mtangirwa et al., 2012; Evans, Menezes et al., 
2013; Nachega, Hislop et al., 2009) or to younger children (Lowenthal et al., 2014). On the 
other hand, in an analysis of the determinants of adherence to cART among HIV-infected 
patients in Côte d'Ivoire, it was reported that 10% of interruptions were related to drug stock-
outs (Diabate S et al., 2007).  Accumulation of treatment-related mutations may be fueled by 
limited access to monitoring of plasma viral load to detect treatment failure much earlier than 
the current public health approach (Hosseinipour et al., 2009; Sigaloff et al., 2011).  
Our study indicated that younger participants are at an increased risk of harboring drug 
resistance mutations compared to adults. Timely actions are called for to design ways for 
early detection and control of drug resistance mutations. More studies are needed to 
understand the links between younger age and presence of treatment related mutations. 
In conclusion, the association between children and HIV drug resistance needs further 
research on what might have caused a higher proportion of children to bear the burden so as to 
find appropriate solutions.  
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Table 10: Participants characteristics (n=163) 
 
 
Variables Overall (163) Children and adolescents (19) Adults (144) 
  n (%) n (%) n (%) 
Sex 
  
  
  Male 50 (30.7) 9 (47.4) 41 (28.5) 
  Female 113 (69.3) 10 (52.6) 103 (71.5) 
Marital status       
   Ever married 114 (71.3) 3 (17.7) 111 (78.2) 
   Never married 46 (28.7) 15 (83.3) 31 (21.8) 
Residence       
   Ifakara town 89 (54.6) 7 (36.8) 82 (56.9) 
   Outside Ifakara town 74 (45.4) 12 (63.2) 62 (43.1) 
Initial ART regimen       
   D4T+3TC+NEV 105 (62.4)   15 (79.0) 90 (62.5) 
   D4T+3TC+EFA   24 (14.7)   1 (5.3) 23 (16.0) 
   AZT+3TC+NEV       4 (2.5)   2 (10.4)  2 (1.4) 
   AZT+3TC+EFA    19 (11.7)   1 (5.3) 18 (12.4) 
   TDF+FTC+EFV         2 (1.2)   0 (0.0) 2 (1.4) 
   Others        9 (5.5)   0 (0.0) 9 (6.3) 
WHO clinical staging       
  Stage 1 61 (37.4) 5 (26.3) 56 (38.9) 
  Stage 11 51 (31.3) 10 (52.6) 41 (28.5) 
  Stage 111 40 (24.5) 4 (21.1) 36 (25) 
  Stage 1V 11 (6.8) 0 (0) 11 (7.6) 
CD4       
  <350 cells/mm3 107 (65.6) 10 (52.6) 97 (67.4) 
  >350 cells/mm3 56 (34.4) 9 (47.4) 47 (32.6) 
Time on ART        
   6-12 months 7 (4.3) 0 (0) 7 (4.9) 
   12-24 Month 25 (15.3) 3 (15.8) 22 (15.3) 
   >24 months 131 (80.4) 16 (84.2) 115 (79.9) 
Viral load       
  >100 copies/mL 9 (5.5) 6 (31.6) 3 (2.1) 
  <100 copies/mL 154 (94.5) 13 (68.4) 141 (97.9) 
 RAM       
  >100 copies/mL 9 (5.5) 6 (31.6) 3 (2.1) 
  <100 copies/mL 154 (94.5) 13 (68.4) 139 (97.9) 
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            Table 11: Predictors of resistance mutations to ART 
 
 
   
 
  ART mutation rates Logistic regression 
 
 
 Variables No mutation (n, %)  Mutation (n, %) OR (95% CI) P-Value 
 
 
 Sex         
 
 
  Male 47 (94) 3 (6) 1   
 
 
  Female 107 (95.5) 5 (4.5) 0.88 (0.21-3.66) 0.859 
 
 
 Residence         
 
 
  Ifakara town 84 (94.4) 5 (5.6) 1   
 
 
  Outside Ifakara town 70 (95.9) 3 (4.1) 0.96 (0.25-3.70) 0.953 
 
 
 Age         
 
 
  Adults 141 (98.2) 2 (1.4) 1   
 
 
  Children 13 (68.4) 6 (31.6) 21.7 (4.9-97.0) <0.001 
 
 
  Initial ART    regimen         
 
 
  D4T containing regimen 123 (96.1) 5 (3.9) 0.50 (0.12-2.13) 0.343 
 
 
  Others* 31 (91.2) 3 (8.8) 1   
 
 
 WHO clinical staging#         
 
 
  Stage I 58 (96.7) 2 (3.3) -   
 
 
  Stage II 46 (90.2) 5 (9.8) -   
 
 
  Stage III 39 (97.5) 1 (2.5) -   
 
 
  Stage IV 11 (100) 0 (0) -   
 
 
 CD4+ cell count         
 
 
  <350 cells/mm3 103 (96.3) 4 (3.7) 1   
 
 
  >350 cells/mm3 51 (92.7) 4 (7.3) 2.5 (0.64-9.8) 0.181 
 
 
 Time on ART (months)         
 
 
   6-24 30 (92.8) 2 (6.3) 1   
 
 
   >24 124 (95.4) 6 (4.6) 0.85 (1.7-4.3) 0.841 
 
 
 Viral non-response         
 
 
  No 154 (100) 0 (0) - - 
 
 
  Yes 0 (0) 8 (100)     
 
 
*AZT+3TC+NEV, TDF+FTC+EFV 
  
  
 
 
 # The limited numbers did not permit meaningful categories for the regression   
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Table 12: Distribution of Resistance associated mutations by age 
Mutation type     ALL 
    (38,100) 
     Children 
      (31,100) 
Adults 
  (6,15) 
 
NRTI  
  
 
 
 
 
 
 
       Column % 
       Row %      
           
 M184V            5 (33.3) 
 L210W            2 (13.3) 
 V75M              2 (13.3) 
 T215Y              2 (13.3) 
 M41L               2 (13.3) 
 Y115F              1 (6.7) 
 L74IL               1 (6.7) 
  
Subtotal             15 (39.5) 
 
         
M184V         4 (28.6) 
L210W         2 (14.3) 
V75M           2 (14.3)  
T215Y          2 (14.3) 
M41L           2 (14.3) 
Y115F          1 (7.1) 
L74IL           1 (7.1) 
 
Subtotal       14 (45.2)  
Subtotal        14 (93.3) 
    
M184V       1 (100) 
 
    
 
 
 
 
 
Subtotal       1 (16.7) 
Subtotal        1 (6.7) 
  
NNRTI 
 
 
 
 
 
 
 
 
 
 
 
 
    Column % 
    Row % 
 
K103N              5 (25) 
A98G                2 (10) 
V108I                2 (10) 
K238T               2 (10) 
V106M              2 (10) 
H221Y               1 (5)      
E138G               1 (5) 
Y181C               1 (5) 
V90I                  1 (5)  
V179D               1 (5)       
F227L                1 (5) 
P225H                1(5) 
 
Subtotal             20 (52.6) 
           
 
K103N          4 (25) 
A98G            2 (12.5) 
V108I            2 (12.5) 
K238T           2 (12.5) 
V106M          1 (6.3) 
H221Y           1 (6.3)  
E138G           1 (6.3) 
Y181C           1 (6.3) 
V90I              1 (6.3)        
P225H            1 (6.3) 
 
 
 
Subtotal        16 (51.6) 
Subtotal         16 (80) 
 
K103N       1(25)  
V106M       1 (25) 
V179D        1 (25) 
 F227L        1 (25) 
 
 
 
 
 
 
 
 
 
Subtotal       4 (50) 
Subtotal       4 (20) 
 
PI 
 
 
 
Column % 
    Row % 
 
L10I                  1 (33.3) 
L33F                 1 (33.3) 
T74S                 1 (33.3) 
 
Subtotal             3 (7.9) 
 
L10I               1 (100) 
 
 
 
Subtotal           1 (3.2) 
Subtotal            1 (33.3) 
 
L33F            1 (50) 
T74S            1 (50) 
 
 
Subtotal          2 (33.3) 
Subtotal          2 (66.7) 
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       Table 13: ART history by age 
 
 
 
 
  
 
ART History Children  Adults 
 
 
  n (%) n (%) 
 
 
D4T+LAM+NEV 216 (35.6) 35 (47.3) 
 
 
D4T+3TC+EFA 126 (20.8) 12 (16.2) 
 
 
AZT+3TC+NEV 8 (1.3) 1 (1.4) 
 
 
AZT+LAM+EFA 57 (9.4) 9 (12.2) 
 
 
TDF+FTC+EFV 55 (9.1) 2 (2.7) 
 
 
TDF+FTC+NVP  4 (0.7) 0 (0) 
 
 
123 53 (8.0) 1 (1.4) 
 
 
ABC+DDL+LPV/R 24 (4.0) 3 (4.1) 
 
 
ABC+DDI+NFV 15 (2.5) 1 (1.4) 
 
 
TDF+FTC+LPV/R 24 (4.0) 4 (5.4) 
 
 
ABC+3TC+LPV/R 5 (0.8) 1 (1.4) 
 
 
OTHER2NDLINE 13 (2.2) 4 (5.4) 
 
 
TDF+3TC+LPV/R 1 (0.2) 1 (1.4) 
 
 
OTHERS 5 (0.8) 0 (0) 
 
 
 *Missing data     
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CHAPTER SEVEN: Discussion and conclusion 
We studied the barriers to successful ART programmes in a resource limited setting. Six years 
after the free ART programme was introduced in Tanzania, issues of access, adherence and 
ART resistance are still of concern. The objectives of the project were to understand the 
supply chain of HIV rapid tests, cotrimoxazole and ART in rural settings; to estimate levels 
and determinants of ART non-adherence and to find predictors of ART resistance-associated 
mutations among HIV positive patients on treatment. Below, we synthesize the study results 
and discuss policy adaptations and programme actions that might address the problems 
identified. Limitations of the study design are discussed, as are potential future research 
activities that could fill the gaps identified in this project. 
The study shows that despite ART decentralization, critical issues in patient management, 
such as stock-outs, need to be addressed. Children and adolescents presented with lower 
adherence rates compared to other participants on ART. This is due to caretaking issues, HIV 
stigma and poverty. In the resistance study, children were shown to be more prone to ART 
genotypic resistances compared to adults. Stock-outs of CTC supplies were evident around 
Kilombero and Ulanga districts in the supply chain paper (chapter three), yet they were not 
reflected directly in the subsequent adherence and resistance studies. Non-adherence was 
attributed, not to stock-outs, but to non-parental caretakers, proximity of CDCI and difficult 
economic experiences. If resistance had been a consequence of stock-outs, all age groups 
would have been affected with ART genotypic resistances in the same proportion. Instead, 
stock-outs were controlled in the CDCI to the extent that it did not contribute to non-
adherence. We are not aware of the status of stock-outs in the peripheral CTCs since the study 
on situational assessment supplies ended.  
ART non-adherence is associated with several risk factors, but living in poverty is common 
among all such cases. Apart from poverty, the study on children showed that living with a 
104 
 
non-parental caretaker and HIV stigma were associated with non-adherence. The other 
adherence study showed newer ART users and patients residing close to the clinic were at risk 
of non-adherence. These findings reveal the different struggles that patients of different ages 
face while on ART. It is widely known that children’s adherence levels rely heavily on the 
caretakers assigned to them (Steele, Nelson et al., 2007). When a non-parental caretaker is 
assigned to be a new adherent assistant to the child, he/she might not be aware of ART’s 
benefits and/or lack experience to play new role. He/she may not assist the patient to take 
drugs as usual or may even overdose the child with ART. New ART users may be subjected 
to the stigma that surrounds HIV disease and must also get used to ART side effects at the 
beginning of the therapy. The difference in risk factors for adherence among different age and 
patient groups is a signal that intervention studies to improve ART adherence should focus on 
these specific factors to effectively address the problems to enable better treatment outcomes. 
Participants in both adherence studies reported non-adherence to ART, with children 
reporting lower adherence compared to adults. This paradox was reflected in the ART 
genotypic resistance study (chapter six), as a larger proportion of children and teenagers had 
genotypic resistance associated mutations than did the adults. Future studies are needed to 
investigate why children are more likely to acquire ART resistance compared to adults. 
There is little evidence from intervention studies, to show that addressing major barriers 
improves adherence among vulnerable groups such as  children and adolescents (Scanlon et 
al., 2013). Studies looking at the effect of food provision and HIV disclosure on adherence 
have yielded positive results (Bikaako-Kajura, Luyirika et al., 2006). Disclosing a child’s HIV 
status is important for long-term disease management and is associated with improved 
adherence and reduced conflict with caregivers (Fetzer et al., 2011). ART programmes should 
consider the best ways to inform the child or potential caretakers of the child’s HIV status and 
ensure that clinics implement the practice. Studies providing food to HIV patients in need 
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have found that HIV disclosure improves adherence (Cantrell et al., 2008). An intervention 
study focussing on the effects of food supplements could be helpful if it targets children and 
adolescents faced with food insecurity. 
Having assessed and analysed information on the assessment of supply chain of HIV test kits, 
cotrimoxazole and ART, adherence and ART resistance, we suggest incorporating the 
following ideas into policy and strategic plans to improve ART management in Tanzania: The 
Global Fund report (The Global Fund, 2011) identified weak forecasting and lengthy 
procurement processes as the main factors behind antiretroviral drug stock-outs in African 
countries. Under-estimating of ART supplies may lead to stock-outs and may cause stress to 
patients and health workers (Supply Chain Management System, 2007). Likewise, over-
estimating can put strains on storage space and may lead to wasting of drugs with limited 
shelf-life (Supply Chain Management System, 2006). There is a need for routine data 
collection on HIV test kits and drugs supplies to estimate the real demand and to enable 
timely ordering of ART items. This method of linking data systems with supply decisions was 
found to be successful in Malawi (Harries et al., 2007). At the programme level, routine data 
collection on HIV test kit and drug supplies can be used to reliably forecast needs and thus 
prevent stock-outs. To ensure cost-effectiveness, correctly estimating the necessary quantity 
of drugs is important. Ensuring there are no pauses in ART supplies, requires a stable supply 
of antiretroviral drugs from the source to the treatment centres.  
Avoiding interruptions in ART supplies requires a stable supply of antiretroviral drugs from 
the source to the treatment centres. Transportation activities within the supply chain should 
include delivery tracking and must account for potential climate conditions. If the clinic is 
without power supply, installing a solar power system would enable data to be entered in a 
timely fashion to help with proper estimations. CTCs should adopt clear and reliable ways of 
conveying information to ART clients during stock-out periods and advise on exactly what 
patients should do and/or where to go. A proper tracking system for patients referred to 
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another clinic can help to ensure that patients actually attend and refill their ART 
prescriptions at the clinic to which they were referred. Such procedures and practices would 
minimise treatment interruptions and loss to follow-up.  
Adopting mobile-health services to report and order items from the supply source would 
improve ART supply chain management by ensuring timely transmission of data to the source 
centre. A lack of reliable and a fast communication tools makes tracking stock levels 
problematic, particularly in remote areas. Short message service (SMS or text messaging) has 
been used to improve drug supply chain management in Kenya and Tanzania. Text messaging 
was used to provide real-time updates on drug stocks in health facilities, reducing stock-outs 
and supporting drug stock management (Barrington et al., 2010; Githinji et al., 2013). In 
developing countries, cellular telecommunication networks and mobile phones have increased 
coverage reaching 79% in 2011 (ICT Indicators database, 2011) making it easier to capitalize 
on and apply the technology. The tool is only effective when transport and communication 
systems can accommodate needs and deliver the required items in time. The ministry of health 
should collaborate with the telecommunication sector in order to agree on terms payment 
arrangements, thereby removing the burden and inconvenience to the CTCs. At the same 
time, the health system should monitor and communicate expired drugs or drugs that are 
about to expire so as to enable early redistribution of the drugs among nearby facilities. The 
system should budget for incentives for staff responsible for stock management and later 
assigned people to do the work under normal circumstances as it was done in the SMS for life 
pilot study (Barrington, Wereko-Brobby et al., 2010).  
Extending ART management training to peripheral CTC staff, emphasising how to handle 
second line drugs and complicated cases at their sites, would be beneficial. Refresher training 
should also be available as changes in ART management arise, guided by informed decisions 
from ongoing research globally. Such training would enrich health care providers with 
sufficient and up-to-date ART knowledge and improve overall delivery of health services. 
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The World Health Organization estimates that the global shortage of trained health care staff 
exceeds four million (WHO, 2010c). For the suggested changes to work there must be a more 
political will, transparency in purchasing and distributing ART and frequent monitoring of 
health facilities by the district Council Health Management Team. (Wales, Tobias et al., 
2014). 
Ensuring optimal adherence levels is essential to avoiding the emergence of drug resistance. 
To detect resistance, low income countries like Tanzania would benefit from cheap tools to 
monitor viral load and genotyping sequencing at the district level. For example, a cheap 
mobile technology that uses recombinase polymerase amplification (RPA) to amplify DNA 
would be a boon in resource limited settings (Rohrman et al., 2015). At clinic level, adherence 
should be closely monitored and information gathered should be acted upon. Patients who do 
not respond to treatment should be directed for sequencing at a specified site. 
The studies conducted and discussed in this work have brought to light important imbalances 
in ART management in Tanzania. They are, however, subject to some limitations. For 
example, in the assessment of supply study (chapter three), we did not interview staff from the 
drug source side, such as staff at the Medical Store Department (MSD) and the District 
Medical Officer (DMO). Thus, our analysis may have missed some other potential factors 
leading to delays in delivering orders to ART clinics or further issues surrounding stock-outs. 
In the adherence study on children and teenagers (chapter four), the decision to group a cohort 
2–19 year olds together might have disguised specific adherence challenges for younger 
children (palatability, caregiver availability), which may be distinct from those for teenagers. 
Since participants aged 18 years and above made up less than 8% of the study population, it is 
unlikely to have biased our results. We caped the adherence limit at 100%; those above were 
categorized in the good adherence group. Technically, it may be argued that they were not 
good adherers as they took the drugs more than required and thus biasing our results in the 
direction of having many adherers while by strict definitions, they were not. In the second 
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adherence study (chapter five), the drop-outs were likely to have been non-adherers, given 
that non-adherence increases risk for mortality and lost to follow-up (LTFU). As a result, the 
group of long-term ART users is a biased selection of the better adhering patients. This study 
misses adherence information of clients who had defaulted from the clinic. In the ART 
resistance study (chapter six), we did not have data on previous ART exposure, which is an 
important explanation of genotypic resistance especially among children. This makes it 
difficult to ascertain the source of resistance mutations. Despite the study design short-
comings, the studies reveal important imbalances in ART management in Tanzania. The 
studies are internally valid, as they measure what was intended. Since some study components 
involved unannounced visits, all children on ART and followed patients over 12 months, we 
believe the data can be generalised to rural areas in SSA. The issues highlighted here may be 
a good starting point for improving ART management in the rural Tanzania and other rural 
areas in SSA with similar experience. 
Gaps in our knowledge remain and should be reconciled through future research on ART. 
Potential areas to be explored include another operational study on assessing the ART supply 
chain, intervention studies to improve adherence, understanding the role of distance to the 
clinic on non-adherence, and establishing why children bear the burden of ART genotypic 
resistance. The study on assessing supply chain management showed stock-outs of ART 
supplies. However, the outcomes were not reflected in subsequent findings and it is important 
to establish why that is the case. As the status of ART supplies may change over time and 
neither our study nor the one done in Iringa (Layer, Kennedy et al., 2014) took into account 
the supply side (MSD), future studies that account for these factors would be valuable. The 
research question to be considered should be “An overall assessment of supply chain 
management of ART in peripheral settings”.  
Findings on ART adherence among children (chapter four) show some patients took more 
drugs than required; it would be of interest to further investigate the dynamics of ART 
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overdose, its role in treatment interruptions and adverse clinical outcomes. Cases of ART 
overdose have been linked to having multiple caregivers (Kikuchi et al., 2014), suicide 
attempts (Krentz et al., 2005), prescribing errors (Commers et al., 2014) and use of unfamiliar 
language on the ART boxes (Iyaji et al., 2008). To our knowledge, there has not been a proper 
analytical study to investigate the problem among children and adolescents in Tanzania. The 
research questions suggested are “Predictors of ART overdose among children and 
adolescents in rural Tanzania”, “Impact of ART overdose in treatment interruption” or 
“comparing treatment outcomes among patient who overdose ART and those who do not”. 
In the second adherence study (chapter five), we found an unexpected association between 
distance to the clinic and non-adherence. Our findings are consistent with those of Wakibi et 
al (Wakibi et al., 2011) who observed in Kenya that patients accessing therapy from ARV 
clinics within walking distance from their residence had poor adherence compared to those 
residing farther away. This warrants a qualitative study as neither study can properly explain 
the mechanism of the association. A research question to be considered should be “Why 
patients staying close to ART clinic fail to adhere to drugs: a qualitative study”. 
There is a need for an intervention study to establish which intervention is best for helping 
ART patients who are struggling to maintain optimal adherence. Data on appropriate 
interventions to improve ART adherence in SSA, especially among children in SSA is 
limited. In 2009, Wamalwa et al showed that medication diaries did not improve ART 
adherence (Wamalwa et al., 2009). The same year, a study by Muller et al. followed patients 
using one of three different ART regimens; none of the interventions were superior in terms 
of adherence (Muller et al., 2009). A successful Community Based Adherence Support 
(CBAS) study in South Africa showed that the intervention did improve adherence and 
treatment outcomes (Fatti et al., 2014; Grimwood et al., 2012). None of these studies targeted 
stigma reduction towards HIV, followed patients for long periods of time or specifically target 
patients at risk of non-adherence (Fetzer, Mupenda et al., 2011).   
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One key to fighting stigma among HIV positive children could be educating their peers and 
influences. An ART education interventional study could target the people who spend the 
most time with the children, such as school mates and teachers, to find out if providing ART 
education improves the situation and change stigma to positive treatment support. To improve 
ART adherence among children, intervention studies should target HIV positive children at 
risk of missing their morning dose because of breakfast-dose timing.  Based on our findings 
that children with non-biological caregivers have lower levels of adherence, usually because 
the assigned caregiver fails to remind the child to take medication, we suggest an intervention 
study that would target orphans and strengthen and motivate the assigned caretaker or recruit 
a community health worker who would be responsible for making sure these children take 
medication while at home (Direct Observed Therapy - DOT). The DOT programme has been 
highly successful in adherence to Tuberculosis therapy. 
Our study on ART resistance showed that children and adolescents are most affected. Further 
investigations are needed to verify this finding in other rural settings and to consider why this 
is the case. 
The studies we conducted over three years highlight important ART achievements, issues and 
research gaps. The findings serve as a basis from which to enrich ART management systems, 
through further investigation and action, in resource limited settings. While the ART 
programme in Tanzania is offered free of charge, HIV patients still incur substantial expenses 
in terms of transport and accommodation to reach and access ART clinics. The study further 
shows that patients from low economic status backgrounds struggle to maintain the required 
level of ART adherence. Shortcomings in the ART supply system need to be addressed to 
avoid stock-outs that lead to poor ART management and treatment outcomes. Discriminating 
against HIV positive individuals has been against the law in Tanzania since April 2008, yet it 
is still common. The stigma associated with HIV discourages some patients from adhering to 
ART. Children on ART face critical challenges when they are not informed of their illness 
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and when those assigned to assist children with their treatment do not do their job. Low levels 
of adherence have led to the emergence of ART genotypic resistance, occurring more 
frequently among children than among adults. We recommend further operational and 
analytical studies to better understand the findings and issues raised in our studies. 
Intervention studies are well suited to finding better ways of increasing ART adherence 
among children in resource limited settings.  
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